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ABSTRACT

FUNCTIONAL PROTEOMIC ANALYSIS OF THE MYOCARDIAL PKCE SUBPROTEOME AND
PKCE-AKT-eNOS SIGNALING MODULES DURING CARDIOPROTECTION

Jun Zhang
September, 2003

Ischemic heart disease is the leading cause of mortality and morbidity in Western societies. Thus,
understanding the molecular mechanisms to reduce myocardial ischemia and limit infarction size
are of great importance. Ample evidence has shown that protein kinase C epsilon (PKCE) play an
essential role in the genesis of cardioprotection. In particular, our laboratory has shown that
activation of PKCE in the heart is sufficient to significantly reduce myocardial infarction due to
coronary artery occlusion. However, the molecular mechanism responsible for PKCE-induced
cardioprotection remain unclear. Recently, functional proteomic analysis have demonstrated that
PKCE forms signaling complexes with various of proteins, including structural proteins, signaling
molecules, stress-activated proteins, transcriptional/translational factors, metabolism-related
proteins, and PKC-binding domain containing proteins, and the coordination of these molecules
contributes to cardioprotection. Despite this information which obtained from whole heart Iysates,
little is known regarding the cellular mechanisms that regulate the assembly of these protein
complexes and the specific manner in which these molecules interact with each. Therefore, this
dissertation is focused on the characterization of PKCE subproteome and Signaling modules
within, as well as their regulation during cardioprotection. PKCE-Akt-eNOS signaling module is
chosen as my research paradigm because the individual molecule PKCE, Akt and eNOS has

v

been implicated in the prevention of cell death. In addition, both eNOS and Akt were found to
exist in the PKC£ complex in our initial studies, suggesting that functional coupling among these
molecules may be a heretofore unrecognized protective signaling mechanism. Our data
demonstrate that the cardiac PKC£ signaling subproteome is comprised of various sizes of
protein complexes, and the formation of these complexes and modules is regulated by the
subcellular localization and extracellular stimulus. During cardioprotection, activation of PKC£
enhances the PKC£-Akt-eNOS module formation, and thus contributes to the regulation of nitric
oxide production and hence the manifestation of the cardioprotective phenotype. In conclusion,
the present research successfully characterizes the myocardial PKC£ subproteome and PKC£Akt-eNOS signaling modules, which serves as an important step towards our complete
understanding of the signaling mechanisms underlying PKC£-mediated cardioprotection and
ultimately aids

in

the

development of pharmacological

Vl

agents to

protect the

heart.

TABLE OF CONTENTS
PAGE
................................. iv
................................. v
................................. ix

ACKNOWLEDGEMENTS
ABSTRACT
LIST OF FIGURES
CHAPTER I. GENERAL INTRODUCTION AND OVERVIEW

1 Proteome, subproteome, and module

...................... 1-4

2. Ischemic injury and cardioprotection

....................... 5

3. Protein kinase C epsilon (PKCE)

....................... 6-9

4. AktlPKB

...................... 10-13

5. Endothelial nitric oxide synthase (eNOS)

...................... 14-16

6. PKCE-Akt-eNOS signaling modules

'"'''''''''''''''''' .17-18

CHAPTER II: METHODS AND MATERIALS

"'''''''''''''''' .... 33-38

CHAPTER III: Functional proteomic mapping of the myocardial PKCE signaling

subproteome in the mouse heart: a subcellular compartment study .
Abstract

.. . . .. .. . .. . . .. .. . .. . '" .................... 39-40

Introduction

........................................... .41-42

Results

............ '" ............................ .43-49

Discussion

...... '., ... '" ...... '" ... '" .............. 50-53

CHAPTER VI: Functional proteomic analysis of myocardial PKCE-Akt-eNOS signaling

modules during cardioprotection.
Abstract

. ..... '" .................. '" .............. 75-76

Introduction

...... '" .................. '" .............. 77-78

Results

................................... , ........ 79-82

Discussion

"'"'''''''''''''''''''''''''''''''''' ..... 83-87
.......................................... 102-115

REFERENCES

vii

.......................................... 116-122

CURRICULUN VITAE

viii

LIST OF FIGURES
FIGURES

1.

PAGE

Functional proteomic platform for isolation and characterization of
multiprotein complexes

.................................................. 19

2.

Molecular structure of Protein kinase C epsilon (PKCE)

3.

Model of activation of PKCE

4.

Activation of PKCE reduces myocardial infarction sizes

5.

Molecular structures and activation model of Akt isoforms .......................................27

6.

Molecular structures of endothelial nitric oxide synthase (eNOS).

7.

Architecture of the cardioprotective PKCE signaling system in cardiac myocytes

8.

Flow chart for isolation and visualization of PKCE signaling multi protein

. ............................................................23

complexes (experimental strategy for Chapter III)
9.

....................................... 21

........................................25

. .......................... 29
........ 31

....................................... 54

Separation protein mixtures from cytosolic and membrane fractions by
two dimensional electrophoresis

.............................................................56

10.

Immunoblotting analysis of known marker proteins in subcellular fractions ................. 58

11.

Characterization of multiprotein PKCE signaling complexes-A

............................. 60

12.

Characterization of multiprotein PKCE signaling complexes-B

............................. 62

13.

Characterization of multiprotein PKCE signaling complexes-C

............................. 64

14.

Demonstration of multiprotein PKCE signaling complexes by liquid chromatography

. ....................................................................... 66
15.

Determination of the native size of multiprotein PKCE complexes ............................. 68

16.

Identification of the molecular components of the multiple PKCE complexes:
examples of eNOS and p170 PI 3-kinase

.................................................70

17.

PKCE directly interact with Akt and eNOS in vitro

18.

Activation of both PKCE and Akt enhanced PKCE-Akt-eNOS modules formation in vitro

. ..................................... 88

............................................................................................ 90
19.

Formation of PKCE-Akt-eNOS signaling modules in vivo

20.

PKCE phosphorylated and enhanced activation of Akt and eNOS in vitro . ................ 94

21.

PKCE directly phosphorylated Akt at its Ser473 site in vitro

. ............... 96

22.

Effect of PKCE on the phosphorylation and activation of Akt in vivo

................ 98

23.

Effect of PKCE on the phosphorylation of eNOS in vivo

. .......................... 92

. ......................... 100

CHAPTER I
General Introduction And Overview

Proteome, subproteome, and module
Upon completion of the human genome project, we have entered the era of proteomics.
Proteomics is the study of the proteome, which was first defined in 1995 as all proteins expressed
by the genome of an organism or tissue (175). Despite the power of genomic technologies, and
the information derived from a sequenced genome, it is clear that proteins are ultimate functional
units within cells, and the coordination of them determines the biological phenotype. Therefore,
mapping the human proteome will bridge the gap between genomics and systems physiology,
and provide tremendous information for diagnostic and therapeutic applications.
The goal of proteomics is to globally map protein expression profiles and protein-protein
interaction profiles within the whole organism (133, 134). However, the generation of proteome
map faces great challenges. First, one gene does not encode a single protein. Indeed, the
number of proteins in the entire human body is expected to be many times higher than that of
genes (81, 96). Second, concomitant co- and post-translational modification events, such as
phosphorylation, glycosylation, sulphonation, palmitoylation, hydroxylation, acetylation and
myristolation et aI., which play critical roles in cellular function, can further increase the complexity
of protein products from a single reading frame. For example, it is estimated that 30% of all
cellular proteins contain covalently bound phosphate (94), and phosphorylation events control the
majority of the Signal transduction pathways in eukaryotic cells. Third, in contrast to the static
genome, the proteome is a dynamic entity that is constantly being modulated by biological and
environmental stimuli (74, 86). Fourth, the architecture of a proteome is both cell and organ
specific. Finally, although significant advances have been made in the development of practical

proteomic techniques, more high-throughput platforms need to be evolved to enhance the power
of current approaches (95). Taken together, mapping the entire proteome is a long-term project
due to its enormity and complexity.
Instead of characterizing every protein within the cell, the goal of functional proteomic

analysis is to analyze the spatial and temporal properties of the specific sets of proteins, called
subproteomes in a cell, tissue, or organism, which are related to the particular biological functions
(73, 170, 173). Compared with the tranditional proteomic analysis, functional proteomic studies
are more feasible and advantageous. Proteins are not separate islands that perform their
functions entirely by themselves. Instead, mounting evidence supports the concept that a protein
may assembly of multi-protein complexes with other proteins to serve as a means to accomplish
complicated tasks of cellular function (3). Characterization of the specific subproteome provides
information about the components of the protein complex, and its dynamic changes, including
protein expression, modification, and subcellular localization, in response to different conditions.
So far, several studies (6, 22, 66, 71, 87, 98, 99, 101, 113, 132, 155) have undertaken the
characterization of different subproteomes, including those defined by the MAPK cascade, the
NMDA receptor complexes, nucleoporin complexes, and the PDGF receptor signaling system.
Within the subproteome, two or more proteins are associated to form a basic functional unit of
signal transduction, called a module, which conducts different tasks at various subcellular
compartments. The formation of many distinct modules contributes to the establishment specific
biological phenotype (170, 172).
A technical platform has been developed in our lab for comprehensive analysis of
functional subproteomes (Figure 1) (135, 170, 171). In order to characterize proteins that
associate with a protein of interest, isolation and purification of protein complexes is the first step.
After subcellular fractionation which is an effective way to reduce the complexity and enrich the
low-abundance proteins, immunoprecipitation and recombinant protein-based affinity pull down
assays are commonly used to isolate protein complexes. Protein complexes are then separated
by one- or two-dimensional electrophoresis, or liquid chromatography, followed by mass
spectrometry or Western blotting to identify components within each complex. Several techniques
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aid the further study of identification proteins, such as confocal microscopy to confirm the
subcellular localization, biochemical in vitro assay to test the protein-protein interaction, and
protein assays to detect the protein expression profiles within the subproteome. Finally,
determination of the functional role of individual protein within the subproteome can link proteomic

data to a physiological phenotype. This step can be conducted by using cell culture or transgenic
animal models, or treatment of activators or inhibitors to test the biological significance of the
protein change in response to the changed environmental conditions.
Similarly, the cardiac proteome is proposed to compose of multiple integrated functional
subproteomes, each of which is organized to facilitate a unique function. Moreover, specific
modules are formed within subproteomes in response to different stimuli (145, 160, 172). Instead
of attempting to Simultaneously examine all proteins in cardiac cells, we focus our research on
characterization myocardial subproteomes that are critically involved in the development of
ischemic injury and cardioprotection, especially the subproteomes of protein kinases associated
with cardioprotection (136, 142, 172). Three aspects are important to characterize a
subproteome: the identification of the proteins that compose the subproteome are classified
according to their biological functions; the molecular architecture of the subproteome, the manner
in which the subproteome is altered in different subcellular locations; and the dynamic modulation
of the subproteome that underlies the development of a specific phenotype. Delineation of
multiple subproteomes based on their respective biological functions and contributions to
phenotypes will eventually lead to full characterization of cardiac proteome.
The goal of this dissertation was to contribute to this understanding of cell signaling in
two fundamental regards. First, as detailed in Chapter III, we wanted to examine the role of
subcellular-dependent regulation of signal transduction by testing the basic hypothesis that the
cell recruits different proteins to regions of the cell to perform specific tasks, and that multiprotein
complexes are involved in this phenomenon. Second, as reported in Chapter IV, we targeted
investigation of a specific signaling module within the cardiomyocyte to test a separate but
equally central hypothesis, namely, that the cell organizes multiple molecules into signal
transduction units (or modules) that are mobilized to accomplish signaling events and to regulate
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phenotype. In this regard, the present dissertation advances our understanding of cell signaling in
general on two critical levels that are interrelated to the common theme of PKCE-mediated
card ioprotection.
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Ischemic injury and

cardioprot.~ction

Ischemic heart disease is the leading cause of mortality and morbidity in Western societies (25).
Thus, mechanisms to reduce myocardial ischemia and to prevent myocytes death are of great
importance to improve patient survival. Due to the limited ability of the heart to regenerate
cardiomyocytes, myocardial cell death is the most deleterious event in the heart. In the past,
numerous attempts had been undertaken to prevent myocardial cell death and limit the infarct
size after a coronary artery occlusion. An endogenous protect live defense mechanism termed
ischemic preconditioning (PC) was discovered in 1986 (128), and exerts a very powerful antiinfarct effect. Ischemic PC is a phenomenon whereby brief ischemic episodes activate an innate
protective system in the heart to render the heart powerfully resistance to subsequent prolonged
lethal ischemic insults. Over the past 16 years, a tremendous evidence has demonstrated that
this protective phenomenon exists in virtually all mammalian nnodels(11, 23). It is hoped that
elucidation of the intracellular signaling mechanisms underlying the myocardial preconditioning
may lead to delivery of effective therapeutic agents capable of reducing the myocardial infarction.
Importantly, cardioprotection can also be engendered by the administration of pharmacological
agents such as nitric oxide (NO) donors in lieu of ischemia (140, 179, 181). NO donor-induced
cardioprotection may have potential clinical applications.
Mounting evidence has demonstrated that protein kinase C epsilon plays a critical role in
the genesis of cardioprotecion (49, 75, 117, 143, 186). In particular, cardiac-specific activation of
PKCc: affords an infarct-sparing effect similar in efficacy to that induced by ischemic and
pharmacological PC. However, the molecular and cellular mechanisms underling PKCE-induced
cardioprotection are poorly understood.
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Protein kinase C epsilon (PKCE)

The protein kinase C (PKC) family of serine-threonine kinases is composed of 12 different
isoforms that are divided into three subgroups based on their regulation. The classical or
conventional PKCs (cPKCs) include the a, PI, PII, y isoforms, and are regulated by Ca 2+,
diacylglycerol (DAG), and phosphatidylserine (PS). The novel PKCs (nPKCs), which include the
E, 8,

Tj,

and

e isoforms,

are regulated by DAG and PS; but are insensitive to Ca

PKCs (aPKCs) include the 1;;,

t,

2

+.

The atypical

and Ie isoforms and are regulated by PS alone. The /l isoform of

PKC (also known as PKD), which is sensitive to both DAG and PS, has been placed into a
separate class because of its unique structural characteristics (12'9) (Figure 2).
Molecular structure of PKCc : Protein kinase C E (PKCE) was first cloned in 1987 and

defined as a novel PKC isoform. Akin to other PKCs isoforms, PKCE consists of two primary
functional domains: an amino-terminal regulatory domain and a carboxyl-terminal catalytic
domain (129) (Figure 2). Within the regulatory domain, there are two C1 regions and one C2
region. The C1 region contains C1A and C1B which form the DAG/phorbol esters binding site via
the cysteine-rich Zn 2 + finger motif. An autoinhibitory pseudosubstrate sequence precedes the C1
domain which can autoinhibit PKCf: to form an inactive closed conformation by occupying the
catalytic substrate-binding cavity. Unlike cPKCs, the C2 region of PKCE lacks the specific
aspartate residues which contribute to the Ca

2

+

binding. Therefore, activation of PKCf: is not

dependent upon the concentration of Ca 2+ ions. The catalytic domain has an ATP-binding site
(C3) and a substrate-binding site (C4), both of which are essential for kinase activity. The hinge
region between C2 and C3 domain can be easily cleaved to release the carboxyl terminal
constitutively active enzyme (kinase domain) when PKCE is membrane-bound (Figure 3).
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Regulation of PKC/:: There are at least three conserved phosphorylation sites within

PKCE that are necessary for the maturation of PKCE and its ability to respond to second
messengers. The first, rate-limiting step is the phosphorylation of Thr566 in the activation loop
(kinase core).

Phosphoinositide-dependent kinase-1

(PDK-1) may be involved

in this

phosphorylation event that leads to the exposure of C-terminus of PKC to the following two
phosphorylation modifications via intracellular autophosphorylation or catalysis by other kinases
(33, 161). These two phosphorylation sites are Thr710 at the turn motif (164), and Ser729 in
hydrophobic site in C-terminus. Phosphorylation of these three sites results in conformational
changes of PKCE that not only lock PKCE into a more thermally stable, protease- and
phosphatase-resistant stage, but also free the

substrate-bindin~l

cavity for pseudosubstrate to

form the closed conformation (Figure 3).
Mature but inactive PKCE localizes in the cytosolic fraction where it is maintained in the
autoinhibited closed conformation. PKCE can be activated by several different second
messengers, including, DAG, PIP 3 (phosphatidylinositol 3,4,5-triphosphate), and fatty acids that
are produced by physiological stimuli such as PDGF (platelet-derived growth factor) and
bradykinin (72, 127). After stimulation, PKCE binds to membrane-associated DAG via its C1
domain. This stimulates the translocation of PKCE from cytosolic fractions to membrane fractions
where C2 region can interact with membrane phosphatidyl serine (PS) (129). This tethering of
both C1 and C2 regions to membrane lipids provide the energy to release the pseudosubstrate
motif from the catalytic domain and open the enzyme's conformation, resulting in maximal PKCE
activation.
Subcellular distribution of PKC/:: The subcellular distribution behavior of PKCE depends

on (i) which second messenger is bound to C1 domain and (ii) which intracellular compartment
the PKCE-specific binding partner, called RACK2 (also known as W-COP), is localized. This latter
molecule binds the C2 (-like) domain of PKCE and modulates its activity. Therefore, both the C1
domain and C2 domain of PKCE function as subcellular localization signals (112). The spatial-

7

and temporal- regulation of PKCE subcellular localization may provide the explanation for its
substrate specificity in the signaling transduction.
Function of PKC£ in non-cardiac cells: PKCE is expressed in many tissues and cells, with

particular abundance in neuronal, hormonal, and immune cells. PKCE has been reported to play
essential roles in a variety of cellular signaling processes (2), including proliferation,
differentiation, gene expression, muscle contraction, mechanical force adaptation, metabolism,
transport, exocytosis, endocytosis, and inflammation. PKCE deficient mice show macrophage
dysfunction due to decreased activation of the transcription factor NF-KB, resulting in increased
mortality after bacterial infection, and indicating the important protective role of PKCE in the
immune system (32). In the neuronal system, PKCE induces neurite outgrowth during neuronal
differentiation through its interaction with actin filaments (106). PKCE has also been implicated in
the regulation of nOCiceptor function that partiCipates in the perception of pain (46). Moreover,
PKCE could promote cell survival and prevent apoptosis through suppression of the exitotoxic
glutamate receptor in neuronal PC12 cells (167), and through dysregulation of the mitochondrial
caspase pathway in lung cancer cells (46).
PKC£ and cardioprotection: In cardiac cells, multiple investigators have found that

activation and translocation of PKCE serves as a central signaling event in the development of
cardiac protection (75, 117, 140-142). In the past several years, studies from our laboratory (140142) have shown that cardiac-specific overexpression of PKCE in transgenic mice hearts can
mimic protection against myocardial infarction by ischemic preconditioning (Figure 4). Studies
based on the cardio-specific transgenic expression of the PKCE-selective translocation inhibitor
(epsilonV1) or activator (\lfepsilon RACK) peptides from other groups also clearly show the
importance of PKCE in the cardiac protection against ischemic damage as well as during normal
postnatal myocardial development (50). Furthermore, moderate ethanol consumption exerts
beneficial cardioprotective effects via mechanisms that involve PKCE activation (188).
Although PKCE has an established role in the genesis of cardioprotection, the molecular
and cellular mechanisms responsible for PKCE-mediated cardiac protection remain unclear.
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Mounting evidence suggests that PKC-dependent protection involves a battery of kinases
(tyrosine kinases, Akt, PI3-K, mitogen-activated protein kinase (MAPKs)) (145, 146, 166), stressactivated proteins (heat shock proteins (HSPs), nitric oxide synthases (NOSs), ion channels, and
pro-survival transcription factors (NF-KB,

HIF-1 ex).

Recently,

using functional proteomic

approaches, our laboratory has demonstrated that PKCE forms signaling complexes with multiple
proteins and that the coordinated action of these molecules confers protection against ischemic
injury (12, 20, 21, 130). In other words, there is a cardiac signaling network centered around
PKCE that is critical for cardioprotection.
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AKT I Protein Kinase B

Akt, also called protein kinase B (PKB), is a serine/threonine kinase, which was first discovered in
1991 by two independent research groups. Akt was initially characterized as the human cellular
homologue of the viral oncogene v-akt from the transforming retrovirus AKT8 (19, 38, 100). To
date, three major isoforms of Akt/PKB have been identified, encoded by three distinct gene loci,
termed Akt1/u, Akt2/P, and Akt3/y. All three isoforms share a high degree of homology at the
amino acid level (42, 103). Akt2 and Akt3 are approximate 82% identical with the Akt1 isoform.
Akt3 lacks 23 amino acids at the C-terminal compared with others (110) (Figure 5). All three
isoforms are ubiquitously expressed in mammals, although levels of expression vary among
tissues. Akt1 is the predominant isoform in most tissues, such as brain, thymus, heart and lung
(19, 38, 100). Akt2 is primarily expressed in the insulin-responsive tissues, such as skeletal
muscle, heart, liver and kidney (7). Expression of Akt3 is more restricted, appearing high in the
brain and testes, and lower in heart, spleen, lung and skeletal muscle. All tissues contain at least
one form of Akt.
Molecular structure of AktlPKB: Examination of the amino acid sequence of AktlPKB
revealed that all three isoforms contain a highly conserved structure. The N-terminal 100 amino
acids posses a pleckstrin homology (PH) domain that mediates lipid-protein or/and protein-protein
interactions. A short glycine-rich region links the PH domain to the catalytic domain. The central
kinase catalytic domain has a conserved phosphorylation site Thr308 (Akt2 Thr309, Akt3 Thr302)
within the activation loop. In C-terminal regulatory domain there is another conserved
phosphorylation site Ser473 (Akt2 Ser474, Akt3 Ser472) (Figure 5).
Regulation of AktlPKB: In the inactive form of Akt, the PH domain serves as an inhibitory
structure that sterically blocks the catalytic site (similar to the antoinhibition of PKCE). Activation of
Akt is initiated by the binding of PIP 3 to the~ PH domain of this enzyme. This action not only
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releases autoinhibition through conformational changes that unmask the active site, but also
recruits Akt to the plasma membrane where it can be further phosphorylated and fully activated.
So far, phosphorylation of Thr308 in the kinase activation loop and Ser473 in the C-terminal
hydrophobic region are the two most important posttranslational modifications. Mutation of

Thr308 to nonphosphorylatable alanine abolishes Akt 's activation, indicating that phosphorylation
of Th308 is essential for activation of Akt. In contrast, mutation of Ser473 only partially inhibits Akt
activation, suggesting that Ser473 phosphorylation facilitates maximal Akt activation but is not a
necessary step in Akt-dependent signaling (5, 138, 183).
Ser124 and Thr450, which are constitutively phosphorylated, were also predicted to be
prerequisite for Akt responsiveness (18), although, mutation of these residues to alanine has no
effect on the activity of Akt (7, 165). In addition, a recent report finds that Src family tyrosine
kinase dependent phosphorylation of two tyrosine residues (Y315, and Y326) may contribute to
the activation of Akt (35).
The cellular activation of AktJPKB is dependent upon the interaction with membranebound second messager PIP 3 The generation of PIP 3 is catalyzed by PI-3K via the
phosphorylation of phosphoinositides (Ptdlns). Although PIP 3 does not activate AktJPKB directly,
it recruits Akt to the plasma membrane and alters the conformation of Akt to facilitate the
subsequent phosphorylation modifications. The upstream kinase that phosphorylates Thr308 is a
67kDa ubiquitously expressed kinase called PDK-1 (5, 162, 163). The role of PDK-1 to activate
Akt has been supported by studies from embryonic stem cells deficient in PDK-1 (177),
biochemical inhibition of PDK-1 (13), and by studies employing anti-sense oligonucleotides
against PDK-1 (59). AktJPKB becomes a substrate for PDK-1 once its PH domain engages PIP 3
on the membrane. Interestingly, as indicated above, PDK-1 is also known to phosphorylate and
activate PKC, though the mechanisms contributing to the specificity of PDK-1 for PKC, Akt, or
other substrates, remain poorly defined.
The upstream kinase for Ser473 phosphorylation is unknown, and is tentatively named
"PDK-2". Several candidate activities have been proposed, including PKC
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s (34,

190), an

unnamed lipid-raft-associated kinase (84), or simply an autophosphorylation processes following
the PDK-1 activity (1).
There are two postulated models for Akt activation. The first mechanism in response to
PI3K induction and PIP 3 production, Akt moves from the cytosol to the plasma membrane, where

Ser473 phosphorylation occurs through autophosphorylation or by PDK2. This region forms a
docking site for PDK-1 to phosphorylate Thr308 and hence activate Akt (8). The second
mechanism is that cytosolic Akt and PDK-1 are co-localized, but Akt is inactive due to constraints
imposed by its PH domain. Growth factors stimulate PI3K, which draw both PDK-1 and Akt to the
plasma membrane. The PH domain of Akt binds to PIP 3 , unmasking the activation loop and
allowing PDK-1 to phosphorylate Thr308. Subsequent elevation of Akt activity promotes
autophosphorylation of Ser473 or by a third-party enzyme (165). Once Akt is activated, it targets
specific proteins in the cytoplasm, plasma membrane and and nucleus (Figure 5).
The consensus motif for Akt phosphorylation is R-x-R-x-x-S/T-F/L (x represents any
amino acid) (5). So far, several potential Akt substrates have been found, such as glycogen
synthase kinase-3 (GSK3), IKB-a kinase a (IKKa), Raf, and Bad. Recently, Akt was found to
regulate the level of nitric oxide (NO) production through direct phosphorylation and activation of
the endothelial isoform of nitric oxide synthase (eNOS) (44, 63).
Subcellular distribution of AktlPKB: The subcellular localization of Akt is tightly regulated.

Two minutes after stimulation by IGF-1, Akt1 is translocated to the plasma membrane in a PH
domain-dependent manner. Prolon~Jed stimulation induces Akt translocated to the nucleus by an
unknown mechanism (8), which is PH-domain-independent.
Function of AktlPKB: Ample evidence shows that Akt is a key player in numerous

physiological and pathophysiological processes, such as gene transcription, protein synthesis,
glycogen synthesis, transcription control, cell growth, cell survival and angiogenesis (26, 28, 44,
62, 63, 67, 69, 121,182). In cardiomyocytes, Akt is activated by gp130 stimulation and has both a
hypertrophic and an antiapoptotic effect (62, 131). Bell and colleagues reported that
administration of bradykinin, as an adjunct to reperfusion, limits infarct size in the mouse heart via
induction of increased activity of Pl3kinase, Akt and eNOS (62). In myocardial gene transfer
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studies, a constitutively active mutant of Akt reduces infarct size and apoptosis after ischemiareperfusion injury (62). Using DNA microarrays, Cook et al (40) reported the cardiac gene
expression profiles in mice with cardiac-specific overexpression of Akt. Studies from these Akt
mice also indicate that Akt exerts a dual function in vivo on the myocardium by increasing both

cardiomyocyte size and contractility (39). They found that chronic Akt activation resulted in the
differential regulation of at least 40 genes in the heart that may contribute to the effects of Akt on
cardiomyocyte survival, metabolism, and growth. Interestingly, studies from Zhou's group find that
moderate alcohol consumption induces sustained cardiac protection is through a PKCE- and Aktdependent signaling pathway (188).

13

Endothelial nitric oxide synthase (eNOS)

Nitric oxide (NO) is a potent messenger molecule that participates in many physiological
processes such as vascular relaxation, neuronal communication, immunological modulation, and
host defense (4). NO is produced from oxidizing L-arginine to generate L-citrulline which is
catalyzed by a family of NO synthases (NOS). There are three distinct isoforms of NOS, referred
to as endothelial NOS (eNOS, NOS-3), neuronal NOS (nNOS, NOS-1), and inducible NOS
(iNOS, NOS-2). eNOS and nNOS are Ca 2+/calmodulin-dependent enzymes producing NO in
short bursts and low concentrations (nM), whereas iNOS produces NO in high concentrations
2

(f.!M) and is Ca +-indenpedent (9).
Molecular structure of eNOS: eNOS was first identified and isolated from bovine aortic

endothelial cells (9, 10) in 1991. Since then, it has been found in many cells, such as platelets
(148), smooth muscle cells (156), cardiac myocytes (14), bone cells, (4) and neurons (27, 45).
According to the amino acid sequence, the primary structure of eNOS has two functional
domains: reductase domain and oxygenase domain. The C-terminal reductase domain (10)
contains NADPH, FAD, FMN, and calmodulin (CaM) binding sites and the N-terminal oxygenase
domain has binding sites for tetrahydrobiopterin (BH4), heme, and L-arginine (14, 27). In
particular, the BH4 domain is reported to be critical for eNOS activity (116, 169), as it is involved
in dimer formation and electron transfer, as well as maintenance of the active site's structural
integrity (Figure 6).
The quaternary structure of eNOS inGiudes its dimerization and association with other
proteins. The eNOS enzyme is the only fully functional in a dimeric form. Dimerization of eNOS
starts with the binding of heme (108), and the binding of BH4, to stabilize the dimer (102, 116,
150). The reductase domain transfers electrons from NADPH via the FAD, FMN and CaM cofactors to the heme in the oxygenase domain. The oxygenase domain catalyzes L-arginine to L-
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citrulline with BH4 binding to O2 . CaM

bindin!~

increases the rate of electron transfer, by which

2

increased intracellular Ca + concentration is required for this protein-protein interaction. Hence,
2

the Ca +/CaM-dependence is one of the features of this particular NOS isoform (Figure 6).
Regulation of eNOS: The regulation of eNOS occurs at three levels: gene transcription,

co/post-translational modification, and allosteric regulation of the enzyme itself.
Transcriptional/translational control alters eNOS protein expression levels via regulation
of the eNOS promoter and altered stability of eNOS mRNA. There are numerous transcription
factor binding sites on the eNOS promoter, including activator protein (AP)-1, nuclear factor (NF)1, nuclear factor-KB (NF-KB). Multiple stimuli can affect the basal expression of eNOS. For
example, hypoxia leads to the activation of AP-1 and induction of eNOS transcription (53, 89).
eNOS levels in endothelial cells also can be efficiently regulated by changes in eNOS mRNA
stability. Hypoxia and cytokines, such as TNF, can downregulate eNOS mRNA levels by reducing
the half-life of eNOS mRNA from 48 h to as little as 3 h (122, 125, 185, 187).
There are several phosphorylation modifications within the eNOS protein. Ser1177
(human) in the reductase domain is the most important one. It is stimulated by the application of
fluid shear stress (44, 64), estrogen (111), VEGF (107), insulin (58), or bradykinin (16) and results
in increased NO production. The kinases involved in this process vary with the stimuli and include
Akt (44, 51), PKA (123), and CaMKl1 (120). In addition, Thr495 within the CaM-binding is
constitutively phosphorylated in endothelium cells, possibly via PKC, and is associated with
decreased eNOS activity (43, 85, 120, 123). Moreover, other phosphorylation sites, such as
Ser114 within the oxygenase domain, are thought to be modified by ERK1/2 (56) and are related
to the dimerization of eNOS. Ser633 and some tyrosine residues can also be phosphorylated, but
the functional significance of these post-translational modifications remains to be determined (44,
56,57).
Lastly, the molecular chaperone HspS10 serves as an allosteric modulator (65) for eNOS
activity. Activation of vascular endothelial growth factor, histamine or fluid shear stress in human
endothelial cell increases the interaction between eNOS and Hsp90, and increases eNOS activity
by approximate 3-fold.
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Subcellular localization of eNOS: eNOS is largely membrane-associated as a result of N-

terminal myristoylation and palmitoylation modifications (30, 152, 157). When eNOS is located in
the caveolae, flask-shaped invaginations of the plasma membrane that occupy up to 30% of cell
surface, it is bound to caveolin. Caveolin is a caveolar resident coat protein that inhibits eNOS
2

activity by interfering with Ca +/CaM binding and electron transfer to the heme subunits (9). In
endothelial cells, eNOS binds to caveolin-1, whereas in cardiac myocytes, eNOS is associated
with caveolin-3. An increase in intracellular Ca 2+ causes the formation of Ca 2+/CaM complexes,
which displaces caveolin resulting in the dissociation of eNOS. At this point, eNOS is now
activated and remains so until intracellular Ca 2+ levels decrease and the Ca 2+/CaM complex can
no longer compete with caveolin. The specific intracellular compartments to which eNOS
translocates remain unclear, but many include the nuclear membrane, the endoplasmic reticulum,
or trans-golgi system (83).
Function of eNOS: The protective effects of NO generated by eNOS are varied. It

regulates vascular tone by relaxation of vascular smooth muscle cells (vasodilation) (76). It
inhibits leukocyte and platelet adhesion and aggregation to endothelium (100) and inhibits
vascular smooth muscle cell proliferation (156).
eNOS is the major form of NOS in the heart and it is expressed in endothelial cells and
cardiac myocytes (14, 105). The protective role of eNOS in the cardiovascular system has been
widely studied. Myocardial overexpression of eNOS in mice greatly stimulates cardiac NO
formation and protects the heart against ischemia/reperfusion injury (29). Moreover, gene transfer
of eNOS to the heart reduces ischemia/reperfusion injury by inhibiting NF-KB activation, adhesion
molecule expression, and the early infiltration of leukocytes (92). In contrast, eNOS knockout
mice exhibit increased left ventricular contractdity in response to ~-adrenergic agonists compared
with wide type mice, demonstrating a negative inotropic effect of eNOS-derived NO (15, 70, 79).
eNOS is also reported to be involved in the development of ischemic preconditioning. Xuan's
2

group report that in conscious rabbit hearts, ischemic PC elicits an immediate activation of Ca +dependent NOS (most likely eNOS), indicatin!J that eNOS serves as a trigger on day 1 to initiate
the development of late PC 24 hours later (18 'I ).
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PKCE-Akt-eNOS signaling modules
As detailed above, PKCE plays a critical role in the genesis of cardioprotection against
myocardial ischemic injury (49, 140-143, 147). Specifically, recent studies in our laboratory
showed that PKCE forms multimeric

signalin!~

complexes with at least 93 proteins, including

structural proteins, stress-activated proteins,

proteins associated with transcription and

translation, proteins involved in cellular metabolism, and various kinases and phosphatases (52,
143). Furthermore, the assembly of these multiprotein PKCE complexes is dynamically modulated
in the PKCE-transgenic mouse hearts, which serves as important evidence for the role of these
complexes in regulating the cardioprotective phenotype.
Importantly, among the 93 known protHin partners, Akt and eNOS are of great interest as
they are well established to independently promote cell survival and prevent cell death in
response to various forms of stress (16, 42, 60, 63, 104, 124, 182). Taken in the context of the
foregoing introduction regarding the essential roles of these three molecules in the cardiovascular
system, the finding that PKCE, Akt and eNOS may be signaling partners in the myocardium was a
tantalizing piece of evidence suggesting functional coupling of these molecules. As a result, we
chose to focus our studies to define the specific role of subcellular dependent regulation of the
PKCE subproteome, and in particular, of PKCE-Akt-eNOS signaling modules within this
subproteome.
Accordingly, my research has focused on the identification of PKCE subproteome, and
the signaling modules within. We hypothesized that PKCE form distinct signaling modules at
different subcellular compartments with different protein components in the mouse heart, and
moreover, that the assembly and activation of signaling modules conduct different tasks which
are essential to the genesis of cardioprotection (Figure 7). In the first part of my research, I
concentrated on the identification of PKCE subproteome in different subcellular compartments,
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and the regulation of these protein complexes during cardioprotection. In the second part of my
study, I focused on the characterization of PKCE-Akt-eNOS signaling modules, which were
chosen as an example to functionally validate a signaling module in cardioprotection.
Previous studies in non-cardiac cells have provided evidence for physical and functional
interaction between PKC, Akt and eNOS. Akt can directly interact and phosphorylate eNOS on
Ser1177 (63). Doornbos' (48) and Mao's (119) groups reported that Akt can be coimmunoprecipitated with PKCs or PKCt, and that the PH domain of Akt is implicated as the
binding site for PKCs to Akt1 (110) and Akt3 (88) in COS-1 cells. Li and colleagues also find that
PKCu overexpression stimulates Akt activity and suppresses apoptosis induced by interleukin 3
withdrawals in myeloid progenitor cells (114). In contrast, Wen (176) reported that in A549 and
HEK293 cells, the phosphatidylinositol 3-kinase/Akt signaling pathway is negatively regulated by
PKC. Similarly, PMA-induced apoptosis is accompanied by an inhibition of Akt activity (149).
Moreover, PKC activation inhibited eNOS activity by attenuating eNOS phosphorylation on
Ser1177 and increasing phosphorylation of Thr495 in cardiovascular endothelial cells (123, 124).
Despite this information, nothing is known regarding the formation and regulation of
PKCE-Akt-eNOS signaling modules in myocytes, especially during cardioprotection. Therefore,
comprehensive investigations need to be implemented to draw a clearer picture of the temporal
and spatial relationship among PKCE, Akt and eNOS in the regulation of NO production and the
genesis of cardioprotection. Successful characterization of myocardial PKCE-Akt-eNOS signaling
modules would serve as a good model for the future research addressing the signaling
mechanisms underlying PKCE-mediated cardioprotection, and of critical importance in the
development of pharmacological agents for the treatment of myocardial ischemia and infarction in
patients. This dissertation provided new information about the molecular architecture of PKCEAkt-eNOS signaling module, the subcellular localization of these modules, and the dynamic
modulation of these modules during the development of the cardioprotective phenotype.
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Figure 1. Functional proteomic platform for isolation and characterization of
multiprotein complexes. This is a hypothesis-driven research strategy to characterize a
cellular subproteome responsible for the genesis of a phenotype. Started with subcellular
fractionation which is an effective way to reduce the complexity and enrich the lowabundance proteins, immunoprecipitation and recombinant protein-based affinity pull
down assays are commonly used to isolate and purify protein complexes. Protein
complexes are then separated by one- or two-dimensional electrophoresis, or liquid
chromatography, followed by mass spectrometry or Western blotting to identify
components within

each

complex.

Then,

biochemical

analyses and

phenotype

assessment are conducted to determine the functional role of individual protein within the
subproteome and link proteomic data to a physiological phenotype. We use this strategy
to characterize the PKCE-dependent signaling mechanisms underlying cardioprotection.
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Figure 2. Molecular structure of protein kinase C epsilon (PKCe). Alike other PKCs,

PKCE has regulatory domain and kinase domain. Within the regulatory domain, an
autoinhibitory pseudosubstrate sequence is ahead of C1 motif (dotted red). 2

nd

messenger DAG and phorbol esters bind to C1 domain; whereas, acidic lipids (PS) binds
to C2 domain. Kinase core has conserved three phosphorylation sites. N is the amino
terminus. C is the carboxyl terminus.
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Figure 3. Model of activation of PKCf:. Newly synthesized immature PKCf: need three
conserved phosphorylation modifications to become maturation which is phosphorylated
by PDK-1 followed by autophosphorylation. Mature but inactive PKCf: localizes in
cytosolic fraction. In response to various stimulus, the generation of DAG and PS recruits
PKCf: to the membrane fraction by engaging the C1 and C2 domains on the membrane.
This membrane interaction provides the energy to release the pseudosubstrate motif
from

the

substrate-binding

cavity,

resulting

PKCf: activation.
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Figure 4. Activation of PKCe reduces myocardial infarction sizes. PKCe transgenic

mice was generated using a-MHC cardiac-specific promoter. The DNA constructs used
in the generation of constitutively active PKCe mutant transgenic mice has a point
mutation at the pseudosubstrate region (A to E at aa159). This mutation would release
psudosubstrate domain from catalytic site, thus placing PKCe in its open, and therefore
active confirmation When these mice were subjected to myocardial ischemia, the PKCe
transgenic mice show significantly decreased myocardial infarction size when
compared with non-transgenic mice, indicating that active PKCe protect the heart.
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Figure 5. Molecular structures and activation model of AktlPKB isoforms. Upper
panel, Akt is also a serine/threonine kinases with three major isoforms. Each isoform
consists of an N-terminal PH domain, a kinase domain and a C-terminal regulatory
domain. N-terminal PH domain can mediate lipid-protein or protein-protein interactions.
Central kinase domain has a conserved phosphorylation site Thr308 which is necessary
for Akt activation. The hydrophobic C-terminal regulatory domain containing a second
regulatory phosphorylation site Ser473, which is required for maximal Akt activation.
Lower panel, inactive Akt mainly resides in the cytosol, and the PH domain is serving as
an autoinhibitory motif to block kinase domain. (like PS for PKCE). The activation of Akt
requires the binding of PIP 3 to PH domain to unmask the kinase domain, leading to the
translocation to membrane fraction;

Akt activation also requires the phosphorylation

modifications of Thr308 and Ser473, which is mediated by kinase called PDK1 and
unknown kinases called PDK-2.

27

AktJPKBu

PH
domain Glycine
PH! rich

e"''''':M,?':;Wj,d~in,a~
:do~ain~
.
- ~.....
,

AktJPKBP

PH

AktJPKBy

PH

f: =: :I"""'~,_""

ReJ~~!~~y

A'.U!. ;~··:Z;Z·H

_

,,:iT,,'
•.•
~.!!\

. ~hr308

,0

..

~73

.. I

~ ,iliilt.IIF'1

Thr309

Ser474
..

~ sc
3!lliiiitiiF -""
., ~",ii'k',,
' .•
-~. ".' . ' . .
" '1
"~A~>
;"~"::i' : . ' ~,F0
~y;;;;'
'- .-;:',.
• ~
.. ~

Ser472

Thr342

!

PI-3K

./'

Translocation

Translocation

.

Translocation

,/'
;""" -:iii+:"

:,., . . '• .;

-,' . .. .;&;"*

!!Sinase' domain. ":'

..-

PP2A

---

II

PH

/

Hrl!<iiiase·i:!Qii'ia1n.dtt~

Active Akt

'\.
Translocation

Inactive Akt

'It

---

CNucleau

00
N

Figure 6. Molecular structure of endothelial nitric oxide synthase (eNOS). eNOS is
2

Ca + -CaM-dependent nitric oxide syntheses, and has two functional domains. C-termianl
reductase domain

and N-terminal oxygenase domain. The myrostoylation (Myr) and

palmitoylation (Palm) sites on eNOS are shown (important features for eNOS membrane
localization), and the autoinhibitory loop within the FMN regions of eNOS is also shown.
eNOS can catalyze arginine to produce nitric oxide. And its activity is highly regulated by
phosphorylation of Ser1177, resulting in an increased activity and increased NO
production.
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Figure 7 Architecture of the cardioprotective PKCe signaling system in
cardiac myocytes. The hypothetical structure of the PKCe signaling subproteome
involves various signaling modules located at multiple subcellular compartments,
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CHAPTER II
METHODS AND MATERIALS

All procedures were performed in accordance with the Animal Research Committee guidelines at
UCLA, which conform with the Guide for the Care and Use of Laboratory Animals, published by
the National Institutes of Health.

Antibodies and Chemicals

Anti- W-adaptin, BMX, caveolin-3, connexin-43, COX-2, desmin, ERK1, HIF-1 a, GM130, Lap2,
MEK1, eNOS, HSP60, iNOS, NuMA, p38 MAPK, p85 PI-3K, p170 PI-3K, PKCE, Pyk2, Ras,
RACK1, and villin antibodies were purchased from Pharmingen (San Diego, CA). Anti-AKAP79,
Akt, ANT1, c-Fos, c-Jun, c-Myc, CREB, Elk, HO-1 HSP27, HSP70, GRP75, hnRNPa2/b1, JNK2,
lamin-C, Lck, NF-KB (p65), PDK1, Src, STAT1 and 3, Tropinin I and T, vimentin, vinculin, Akt1/2,
Akt1, Akt2 and Akt3 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Anti-aB-crystallin and TCP-a (RACK2) antibodies were purchased from Stressgen
(Vancouver, BC). Anti-phospho-Akt of Ser308 and Ser 473, anti-phospho-eNOS (Ser1177)
antibodies and Akt kinase assay kit were from Cell Signaling Technology Inc. (Beverly, MA). Antia-actin and a-actin in antibodies from Sigma-Aldrich (St. Louis, MO). Anti-Na+/K+ ATPase, histone
H4, PP2A, PP1 antibodies were purchased from Upstate Biotechnology (Lake Placid, NY), antiprohibitin-1

antibody from

Research Diagnostics (Flanders, NJ), and anti-VDAC1

from

calbiochem (San Diego, CA). Anti-ribonucleoprotein (RNP) antibody was from NeoMarkers
(Fremont, CA), anti-glyceraldehydes-3-PDH (GAPDH) antibody was from Biodesign (Saco,
Maine), and anti-creatine kinase was from abcam (Cambridge, UK). The aldose reductase
antibody was a generous gift from Dr. Aruni Bhatnagar (University of Louisville). The hnRNPH1
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antibody and hnRNP K antibody were generous gifts from Dr. Doug Black (Howard Hughes
Medical Institutes, CA), and Dr. Pradip Raychaudhuri (University of Illinois at Chicago),
respectively. The Oracle antibody was custom made by BioSource (Camarillo, CA). Cross-linker
EZ-Link Sulfo-NHS-LC-Biotin and streptavidin:HRP were obtained from Pierce (Rockford, IL). Larginine, Bistris, tricine, sucrose, 6-aminocaprioc acid, and other chemicals were purchased from
Sigma-Aldrich. Recombinant active Akt, unactive Akt, PH domain of Akt, PH domain deleted Akt
were purchased from Upstate Biotechnology (Lake Placid, NY). Recombinant PKCE and eNOS
were bought from Biomol (Plymouth meeting, PA) and Calbiochem (La Jolla, CA), respectively.

PKCe Transgenic Mice

The cardiac-targeted PKCE transgenic mice used in these studies have been previously
described (142, 145). This transgenic line exhibits moderate increases in PKCE activity, is
inherently cardiac protected, and is free from hypertrophy. Transgenic mice and their nontransgenic littermates were used at 9-12 weeks.

Subcellular fractionation

All fractionation procedures were performed at 4°C. Myocardial cytosolic, nuclear, mitochondrial,
membrane fractions were obtained by differential centrifugation as previously described (12).
Briefly, mouse hearts were homogenized in buffer containing 250mM sucrose, 10mM Tris-HCI
(pH?.4), 1mM EDTA, 1mM NaN04, and a cocktail of protease inhibitors (Roche, Indianapolis,
IN). The homogenate was then centrifuged at 1000 x g for 10 min to pellet the nuclear fraction.
The supernatant was centrifuged at 10,000 x g for 30 min to yield the mitochondrial fraction in the
pellet (12). The resultant supernatant was subsequently centrifuged at 100,000 x g for 1 hr to
yield the cytosolic fraction (supernatant) and membrane fraction (pellet). The different membrane
fractions were then re-suspended in homogenization buffer with 0.5% (v/v) NP-40. Caveolae
were isolated by differential density centrifugation, as described by Smart et al (159).
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Immunoprecipitation

PKCE monoclonal antibodies were covalently cross-linked to protein-AiG beads (Santa Cruz)
using a commercially available kit (Pierce). Subcellular Iysates (1000/1g) were incubated with the
immobilized PKCE antibody overnight at 4°C and washed three times with buffer containing 150
mM NaCI, 20 mM Tris-HCI (pH 7.4), 10 mM EOTA, 1 % (v/v) NP-40, 1 mM NaN04, and a
protease inhibitor cocktail (Roche). After the final wash, the beads were re-suspended in laemmli
buffer, boiled for 10 min, and then the supernatants were subjected to SOS-PAGE and
immunoblotting. If immunoprecipitation was followed by two dimensional (20) electrophoresic
analysis, after the final wash, the beads were washed with 10% sucrose to remove salt, and the
protein complexes then dissolved into thiourea buffer (Urea 7M, thiourea 2M, CHAPS 2% (w/v) ,
OTT 65mM, Zwittergent 1% (v/v), Ampholytes (pH3-10) 0.8% (w/v) , and bromphenol blue 0.01 %
(w/v) (Genomic Solutions, Ann Arbor, MI).

Immunoblotting

Samples were denatured in laemmli buffer, resolved by one-dimensional SOS-PAGE, and
transferred onto nitrocellulose membranes. After blocking with 5% (w/v) nonfat milk powder, the
membranes were immunoblotted using the ECl detection system (Amersham, Piscataway, NJ).

Two-Dimensional Electrophoresis

Subcellular extracts were loaded onto immobilized pH gradient (IPG) strips (Amersham) and
subjected to isoelectric focusing in the first dimension as described (142). The IPG strips were reequilibrated and subjected to SOS-PAGE (Genomic Solutions) for the second dimension.
Proteins were then visualized by silver staining.

Protein Biotinylation

Following PKCE immunoprecipitation, protein complexes were eluted with low pH elution buffer
(Pierce) and then dialyzed against PBS overnight at 4°C. To biotinylate the proteins, the dialyzed
sample was incubated with EZ-Link Sulfo-NHS-lC-Biotin (Pierce) at 4°C for 4 hours. The
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samples were then subjected to SDS-PAGE, transferred to nitrocellulose membranes, and
visualized using streptavidin-HRP (Pierce) and the ECl system (Amersham).

Gel Filtration Chromatography

Gel filtration chromatography was carried out as described (36) with a few modifications
Subcellular fractionations which were prepared from 15 hearts in Buffer A containing: 20mM
HEPES, pH 7.9, 1.5mM MgCI 2 , 150mM NaCI, 0.2mM EDTA, 0.5% (v/v) NP-40, and a cocktail of
protease inhibitors, or total homogenates from two mouse hearts were dialyzed overnight at 4°C
in Buffer A without NP-40, and clarified prior to chromatography. These samples were then
loaded onto a pre-calibrated Sephacryl S-400 column (XK 26/70, 26 mm diameter, 70 cm length,
Amersham) using Buffer A without NP-40 as running buffer. Each 1ml fraction was collected.
Proteins were then precipitated with cold acetone, and analyzed by either SDS-PAGE or native
gel electrophoresis. Thyroglobulin (669kDa), Ferritin (440kDa), catalase (232kDa) and aldolase
(158kDa) (Pharmacia) were used as molecular standards.

Native Gel Electrophoresis

Native gel electrophoresis was carried out as described (153, 154) with minor modifications. In
particular, deoxycholic acid was used in place of Coomassie blue. Gel filtration fractions were
precipitated with cold acetone and then solubilized in buffer containing 50mM 6-aminocaproic
acid, 200mM Bis-Tris, pH 7.0, 20% (v/v) glycerol, and 0.5% (v/v) NP-40 for 1 hour on ice. Then
samples were mixed with 10x native sample buffer containing 100mM Bis-Tris, pH 7.0, 1M 6aminocaproic acid, 35% (v/v) glycerol, and 1.0% (v/v) deoxycholic acid. After clarification, the
samples were loaded onto 5-13% gradient native gels. Electrophoresis was performed at 100
Volts with 15mA per gel overnight at 4°C. Thyroglobulin (669kDa), Ferritin (440kDa), and catalase
(232kDa) (Pharmacia) were used as molecular standards.
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GST-PKC& Pull-Down

GST-PKCe affinity pull-down assays were performed as previously reported (142). Briefly, GSTPKCe recombinant protein was generated using the baculovirus system (Pharmingen).
Subcellular fractions were incubated with GST-PKCe in binding buffer containing 0.5% (v/v) Triton
X-100, 20mM Tris-HCI, pH7.4, 150mM NaCI, 1mM EOTA, 1mM EGTA, and a cocktail of protease
inhibitors (Roche) overnight at 4°C. The beads were washed three times and the proteins eluted
with glutathione (GSH) elution buffer (Pharmingen).

Sucrose Gradient Purification

Proteins eluted from the GST -PKCe pull-down were overlayed on a 10-30% sucrose gradient
(132). Eighteen consecutive fractions, beginning from the top, were collected. Thyroglobulin
(669kOa) and catalase (232kOa) were used as molecular standards. Protein fractions were
precipitated with cold 10% (w/v) TCA and 90% (v/v) acetone, resolved by SOS-PAGE, and
visualized by silver staining. To identify PKCe signaling complexes, the SOS-PAGE was blotted
by PKCf antibodies.

Phosphorylation of Akt or eNOS by PKC&

Recombinant Akt or eNOS was incubated with PKCe in PKC reaction buffer containing 0.03mg/ml
La-phosphatidyl-L-serine, 2.51lg/ml phorbol 12-myristate 13-acetate, 3.5mM dithiothreitol (OTT),
100llM ATP, 6.5mM magnesium chloride, 50mM Tris-HCI, pH7.5 at 30°C for 30min. The reaction
was terminated by addition of 5xLaemmii sample buffer and boiled 5 min at 90°C. The proteins
were then separated by SOS-polyacrylamide gel electrophoresis (PAGE), dried and exposed to
X-ray films.

Akt Activity Assay

Akt kinase activity assay was measured using a commercial available kit from Cell Signaling.
Briefly, Akt immunoprecipitant were incubated with 11lg GSK-3 fusion protein in the presence of
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ATP and kinase assay buffer containing 25mM Tris·HCI (pH 7.5), 5mM 0-glycerolphosphate,
2mM dithiothreitol, 0.1 mM NaN04, 10mM MgCI2 at 30°C for 30 min. Phosphorylation of GSK-3 is
measured by Western blotting using a phosphor-GSK-3 (Ser21/9) antibody.

eNOS Activity Assay

eNOS activity was assayed via measuring NO z/N0 3 production using colorimetric assay kit from
Calbiochem.

Briefly,

incubate

recombinant

eNOS

with/out

pretreatment

or

eNOS

immunoprecipitant from mouse heart with reaction buffer containing 1.25mM NADPH, 1.25mM
arginine, 0.5mM CaCI 2, 311M tetrahydrobiopterin (BH4), 111M flavin adenine dinucleotide, 111M
flavin adenine mononucleotide and 25mM Tris-HCI, pH7.4 for 30 min at 30°C. Then nitrate was
conversed to nitrite with nitrate reductase treatment. Total nitrite was measured by using the
Griess reaction as modified by Gilliam et al (68).

Statistical Analysis

Data are reported as mean±SEM. Differences among the 4 experimental groups were analyzed
using one-way ANOVA. If the ANOVA showed an overall significance, post hoc contrasts were
performed with Student t tests for unpaired data using the Bonferroni correction (174).
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CHAPTER III
Functional proteomic mapping of the myocardial PKC& signaling
subproteome in the mouse heart: a subcellular compartment
study
Abstract
Functional proteomic analyses have revealed that protein kinase CE (PKCE), a critical mediator of
cardiac protection, forms multiprotein signaling complexes in the myocardium. We previously
characterized at least 93 PKCE-associated proteins in the PKC€ signaling subproteome including
structural proteins, signaling molecules, stress-activated proteins, transcriptional/translational
factors, metabolism-related proteins, and PKC-binding domain containing proteins. However,
these studies were performed in the context of the whole myocyte, and information regarding the
subcellular distribution of these proteins, which is essential for the construction of a cellular map
of this subproteome, was lacking. The present studies were designed to investigate the
localization and composition of PKCE complexes in each subcellular compartment and the
putative mechanisms that govern their assembly. Accordingly, we examined three critical aspects
of multiprotein complexes in the myocardium: the molecular size of native protein complexes; the
molecular composition of individual protein complexes, and the assembly of each complex in
various cellular compartments. Furthermore, the functional significance of these complexes was
assessed by delineating their formation in the genesis of a cardioprotective phenotype. Using a
comprehensive functional proteomic strategy that combines various protein isolation, separation,
and identification techniques, we found that: 1) the cardiac PKC€ signaling subproteome is
comprised of various multiprotein PKC€ complexes; 2) the native size of each PKCE complex
differs over a wide range of molecular weight among cytosolic, membrane, nuclear,

39

mitochondrial, and caveolar compartments; 3) different PKC€ complexes appear to have distinct
molecular compositions, which vary with subcellular location, suggesting that subcellular location
contributes to the identity of PKC€-associating proteins; and 4) the assembly of these complexes
is dynamically modulated in the cardioprotected when compared with the normal heart. Taken
together, our data represent the first comprehensive analysis of subcellular PKC8 protein
complexes and demonstrate that formation of these signaling complexes is subcellular
compartment-specific.
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Introduction

Molecular interactions among proteins serve as essential mechanisms to facilitate the
transmission of messages within the cell. Functional proteomic analyses of several signal
transduction systems in various cell types have advanced our understanding of how such
messages are relayed (91, 97-99, 113, 142, 168, 173). Whereas the majority of previous studies
have examined the functional interaction of only limited molecules, proteomic analysis of an entire
subproteome enables delineation of complex molecular interactions in both normal and diseased
states, providing a more comprehensive picture of how a given signaling network operates. For
instance, an investigation by Husi et al. identified 77 proteins within the brain NMDA receptor
complex, which include cytoskeletal, adaptor, and signaling molecules (98, 99). In a different
study, several proteins, ranging from DNA repair to cytoskeletal regulation, were found to
undergo expression and/or post-translational alterations following either activation or inhibition of
the serine/threonine protein kinase MEK, a key component of the ERK pathway (113).
Recently, our laboratory has used functional proteomics to study myocardial signaling
(52, 142). These analyses of the cardiac PKCE signaling subproteome revealed that PKCE forms
multimeric signaling complexes with at least 93 proteins, which can be categorized as structural
proteins,

signaling

molecules,

stress-responsive

proteins,

metabolism-related

proteins,

transcription- and translation-related proteins, and PKCE binding domain-containing proteins (52,
142). Moreover, cardiac protection facilitated by transgenic activation of PKCE was concomitant
with altered recruitment and post-translational modification of many protein residents within the
PKCE complexes. Together, these studies indicate that a given signaling element, such as PKCE,
can interact with and modulate a wide range of proteins, diverse in both structure and biological
function.
Recent studies have demonstrated that subcellular compartmentalization is a critical
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factor in defining signaling specificity (97, 173). Therefore, the delineation of a detailed cellular
map of a signaling system would be of essential importance to our understanding on how this
system supports a biological function. Using whole cardiac cell Iysates (52, 142), our previous
studies identified many molecular participants that comprise the cardiac PKCE signaling
subproteome, however, information regarding the subcellular localization of PKCE associated
proteins, which is essential to the mapping of this subproteome, is unknown. The formation and
activation of specific PKCE signaling complexes at different subcellular compartments has been
implicated to have significant functional consequences (12, 172, 173). Characterization of the
subcellular distribution of PKCE complexes should provide key insights into the signaling
mechanisms underlying the cardiac phenotypes observed in response to PKCE activation.
Accordingly, in the present study, a systematic examination of PKCE complexes was
conducted in the cytosolic, nuclear, mitochondrial, membrane, and caveolar subcellular fractions
of mouse hearts, with regard to both their native sizes and their protein compositions. Moreover,
the dynamic modulation of each subcellular PKCE signaling complex in response to a phenotypic
change was also assessed using cardiac protected PKCE transgenic mice that have been
previously established in our laboratory (Figure 8). Our data provides critical information to the
mapping of the cardioprotective PKCE signaling subproteome in the murine myocardium.
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Results
Subcellular fractionation of mouse hearts and isolation of multiprotein PKCE complexes.
Mouse hearts from

transgenic PKCe (TG) and nontransgenic (NTG) littermates were

homogenized and the Iysates were fractionated by differential centrifugation methods into
cytosolic, nuclear, mitochondrial, membrane and caveolar fractions. 20 electrophoresis followed
by silver staining revealed largely disparate patterns of proteins among various subcellular
fractions (Figure 9). To verify the subcellular fractionation processes, immunoblotting for
subcellular compartment-specific proteins was carried out for each fraction. The nuclear-specific
protein NuMA was only found in the nuclear fraction, whereas the sarcolemmal Na+/K+ ATPase
was primarily localized in the membrane fraction, and the mitochondrial protein prohibitin-1 was
mainly concentrated in the mitochondria (Figure 10). Finally, cytosolic separation was assessed
using lactate dehydrogenase (LOH) activity, with >98% of the total LOH activity residing in the
cytosolic fraction, and only :::;0.85% activity present in any of the other cellular fractions (Figure
10). Therefore, our subcellular fractionation procedure was largely efficient with minimum crosscontam ination.
We next examined PKCE expression in each subcellular fraction from both NTG and TG
hearts by immunoprecipitating PKCe and then immunoblotting for PKCe. Figure 11 shows that
PKCe could be efficiently immunoprecipitated from each fraction, which enabled isolation of
multiprotein PKCe complexes for further studies in a subcellular-specific manner. As expected the
levels of PKCe in every compartment were considerably higher in the TG mouse hearts when
compared with the NTG mouse hearts.
Following immunoprecipitation, multiprotein PKCe complexes from different subcellular
fractions were eluted and visualized by either 10 SOS-PAGE (Figure 12) or 20 PAGE (Figure 13)
followed by silver-staining. Figure 12 illustrates significant differences in PKC!:-associated
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proteins in the cytosolic, nuclear, mitochondrial, and membrane subcellular compartments. These
differences include the number of proteins present within each subcellular PKCE complex as well
as the molecular weights of proteins within each subcellular PKCE complex. A similar trend was
found following 20 separation, examples of which are shown in Figure 13. Multiprotein PKCE
complexes from cytosolic and nuclear fractions displayed distinct 2D electrophoretic patterns of
protein spots. Taken together, our results show that each subcellular fraction contains PKCe
signaling complexes. Moreover, our data show that the number and size of the proteins within the
PKCe complexes differs in each subcellular compartment. The nature of such differences

highlights potential subcellular-specific differences in PKCe dependent signal transduction and
cellular function.

Delineation of the physical sizes of native multi protein PKCe complexes.

Having validated the subcellular fractionation and complex isolation procedures, large-scale
homogenization and fractionation of NTG mouse hearts were performed. Subcellular protein
mixtures from 15 hearts were analyzed by gel filtration chromatography using a Sephacryl S400
column to separate intact protein complexes on the basis of their physical size. The presence of
multiprotein PKCe complexes in the different subcellular fractions was then determined by PKCe
immunoblotting. Figure 14 shows the chromatographic profiles of PKCe protein complexes in
cytosolic, membrane, mitochondrial, and nuclear fractions, respectively. Although a significant
amount of PKCe migrated in the form of either a monomer or a dimer (elution volumes 250280ml), especially in the cytosolic and nuclear fractions, the migration pattern of PKCe at lower
elution volumes demonstrated that PKCe associates with many other proteins in different sized
complexes. The most striking finding was that the elution profiles of PKCe protein complexes
were very different in each subcellular fraction, again emphasizing the heterogeneity of
multiprotein PKCe complexes, both in size and composition, among compartments.
Individual fractions separated by gel filtration were further analyzed for PKCe complex
formation. After immunoprecipitation with PKCe antibodies, PKCe complex proteins were eluted
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and cross-linked with a Sulfo-NHS-LC-Siotin conjugating agent. The biotinylated proteins were
then separated by 1D SDS-PAGE and visualized by immunoblotting using a streptavidin-HRP
conjugate (Figure 15a). The results confirmed that PKCE associates with a battery of proteins in
the mouse heart. Again, it was evident that the collection of proteins within the PKC£ complexes
differed across individual subcellular compartments. As expected, the larger complexes were
found in the lower elution volumes and contained more components in general; whereas the
smaller complexes were found in the higher elution volumes and hosted fewer proteins.
To insure that our findings regarding these complexes were not due to protein
aggregation artifacts, we performed additional experiments to study these multiprotein complexes
using recombinant GST-PKCE as bait proteins. Cardiac subcellular fractions were incubated with
GST-PKC£ fusion proteins and allowed to form complexes. These complexes were then isolated
from the cell lysate by GST pull-down and further fractionated by sucrose gradient centrifugation.
Gel analysis and immunoblotting of sucrose gradient fractions showed that in all subcellular
compartments (Figure 15b shows cytosolic as an example), GST-PKC£ forms specific
multiprotein complexes of varying sizes. The peak sedimentation fraction for PKC£ appeared to
migrate at -200kDa; however, PKC£ containing fractions were also traced at higher weights
(>669kDa), showing that large complexes were also formed (Figure 15b). In further complex
formation tests, analysis of two selective fractions from gel filtration by deoxycholate-buffered
native gel separation definitively show that PKC£ is present in several high molecular weight
complexes (>880kDa). Combined with the expression profile of each subcellular fractionate
generated by gel filtration, these data show that PKC£ forms numerous complexes in each
compartment that are largely heterogeneous in size and molecular weight (Figure 15c).

Characterization of protein compositions of subcellular PKC£ complexes in the mouse
heart
In order to assess the identity of the proteins within the subcellular PKC£ complexes, PKC£ was
immunoprecipitated from each fraction and the complexes analyzed by immunoblotting for
proteins previously demonstrated to be components of the total cardiac PKC£ complex (52, 142).
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Protein expression profiles of the PKC& signaling complexes in cytosol

The number of proteins constituting the cytosolic PKCE signaling complex was extensive (Table
1). Many contractile proteins found in the soluble fraction, such as troponin I and actin, resided in
the PKCE complex. Interestingly, RACK2 and AKAP79, which are anchoring proteins for several
kinases, including PKC, were also associated with cytosolic PKCE complexes. Moreover, many
signaling proteins interacted with cytosolic PKCE including lipid kinases (e.g. PI 3-kinase) (Figure
16), tyrosine kinases (e.g. Lck, Pyk2), serine/threonine kinases (e.g. Akt, MAPK), and protein
phosphatases (e.g. PP1, PP2A). Stress-activated proteins involved in the synthesis of low
molecular weight mediators such as nitric oxide (eNOS) (Figure 16), prostaglandins (COX2), and
carbon monoxide (HO-1) were also key components, alongside several members of the heat
shock protein family (HSP70, HSP27). The hypoxia sensitive transcription factor Hif-1 a was also
found in the cytosolic complex, consistent with the cytoplasmic localization of Hif-1 a in quiescent
cells (37), as were multiple metabolic proteins, such as creatine kinase.

Protein expression profiles of the PKC& signaling complexes in nucleus

The nuclear PKCE complex was as extensive in composition as the cytosolic fraction (Table 1).
Not surprisingly, the nuclear proteins LAP2, NuMA, and lamin C bound to PKCE in this fraction. A
similar profile of signaling kinases and stress-activated proteins that was seen in the cytosol was
also observed in the nuclear signaling complex. However, unlike the soluble fraction, we also
found the tyrosine kinases Src and BMX in the nuclear PKCE complex. In addition, multiple
transcriptional proteins resided in the nuclear PKCE complex, including c-Fos, c-Jun, NF-KB, Elk1, CREB, and STATs.

Protein expression profiles of the PKC& signaling complexes in membrane

Consistent with the hypothesis that RACK proteins mediate PKCE translocation to membranous
structures, we found both RACK1 and RACK2 in the membrane PKCE complex (Table 1).
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AKAP79 also co-localized with PKCe complex in this compartment. Other structural proteins in
the membrane complexes included the intermediate filament protein desmin, the tight junction
protein villin, the Golgi matrix protein GM130, and W-adaptin, a constituent of clathrin-coated pits.
Along with the many kinases and stress-activated proteins already observed in the cytosolic and
nuclear complexes, the cardiac-specific gap junction protein connexin-43 also interacted with
PKCe in the membrane.

Protein expression profiles of the PKC& signaling complexes in caveolae

Although the cytosolic, nuclear, and membranous PKCe signaling complexes contained a large
number of molecules, we found that the expression profile of proteins in the caveolar PKCe
complex was by comparison limited (Table 1). The structural protein caveolin-3 was a major
component of the PKCe complex in this specialized micro-domain. RACK2 and W-adaptin were
also found. Again, several kinases were associated with PKCe in caveolae including Ras, and
Akt, the tyrosine kinases Src and Lck, and all three MAPK families. In agreement with previous
investigations demonstrating strong caveolar localization of NOS (80,151), both eNOS and iNOS
interacted with PKCe in mouse cardiac caveolae (Figure 7).

Protein expression profiles of the PKC& signaling complexes in mitochondria

Our initial analysis revealed number of PKC€ associating proteins in the mitochondrial fraction
(Table 1). Notably that these proteins include the mitochondrial import protein, prohibitin-1, and
the mitochondrial metabolic proteins ANT, VDAC, and isocitrate dehydrogenase. In addition, the
signaling kinase profile of the mitochondrial PKCe complex contained multiple tyrosine kinases,
as well as members of the MAPK and Akt signaling pathways. There were also a number of
stress proteins associating with PKCe in the mitochondria, all pertaining to mediator synthesis
and metabolism, such eNOS (Figure 7) and COX2.
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Modulation of subcellular PKCe complexes size in protected myocardium.

It has been previously demonstrated that cardiac-specific transgenic activation of PKCE renders
the mouse heart resistant to ischemiaireperfusion injury (136, 142, 145). In addition, analysis of
the PKCE complexes from the total cell Iysates of protected hearts and wild type mouse hearts
showed alterations in the interaction of many proteins with these complexes (52, 142). However,
it remained unknown what mechanisms regulated the association of given proteins with PKCE.
Thus, the present study investigated the role of subcellular location as a regulatory determinant of
the formation of these complexes during phenotypic changes. Gel filtration experiments were
performed using PKCE TG mice hearts and then compared to those conducted with NTG mouse
hearts to determine the alterations of native subcellular PKCE complexes during cardiac
protection. As seen in Figure 6, the native protein profiles of PKCE complexes in TG hearts were
also subcellular compartment-specific. In general, the size of native PKCE complexes were
increased in the PKCE cardioprotected hearts, with a concomitant decrease in the free forms, that
is, the monomeric and dimeric forms, of PKCE, further supporting the concept that protective
PKCE signaling involves the recruitment of proteins into these complexes. In particular, in the
cytosolic fraction, PKCE formed putatively several very high molecular weight (>MDa) complexes
in the TG heart that were not present in the NTG heart. The mitochondrial, membrane, and
nuclear PKCE profiles also exhibited dramatic changes in the TG mouse hearts compared with
those in NTG hearts. Taken together, these data indicate that PKCE recruits different molecules
into the complexes depending on the subcellular location and that the subcellular complexes are
individually modified in the protected versus the na'fve heart. This finding suggests that this
subcellular organization of multiprotein signaling complexes contributes to the simultaneous
modulation of multiple functions that lead to a given phenotype, in this case cardiac protection.
In addition to modulation of native PKCE complex size, the composition of each PKCE
complex was altered in a subcellular-specific manner in the TG mouse hearts. Indeed, striking
variation in the expression profiles of PKCE complexes was observed across different cardiac
subcellular locations when normal hearts were compared to those protected against ischemic
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injury (Table 2). Enhanced binding of a variety of signaling and stress-activated molecules to
PKCe was for the most part subcellular compartment-specific. For example, eNOS was
upregulated in all the subcellular PKCe complexes whereas the 170kDa isoform of PI 3-kinase
was only increased in the cytosolic and membrane fractions (Figure 16). Regarding structural
proteins, the PKCe-selective receptor protein, RACK2 exhibited greater interaction with PKCe in
both the cytosol and the membrane fraction of the TG mouse hearts, whereas interaction of PKCe
with the LlM/PDZ-containing protein Oracle, a protein that has been characterized in cardiac
development (93, 137, 189), was only elevated in the nuclear fraction. The upregulation of these
specific proteins in specific subcellular complexes points to the ability of PKCe to modulate
multiple, discrete cellular functions.
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Discussion
Although several efforts in whole organelle proteomic analyses of mitochondria (12, 77,
118), Golgi (17, 178) and other subcellular fractions (36, 90, 109, 126, 131, 139) have achieved
fruitful results, comprehensive characterization of the entire proteome of a particular organelle
remains a Herculean task. Major challenges include the dynamic nature of these organelle
proteomes with respect to the changes of time and cellular functions. In contrast, studies focusing
on the examination of specific subproteomes, such as the PKCE signaling system, will target a
sub-group of proteins on the basis of the specific biological functions they perform and will define
temporal alterations of these proteins (during the time course of a phenotype change).
Consequently, this approach is more focused and will enable us to circumvent the
aforementioned challenges. In accord with this concept, simultaneous proteomic analysis of a
particular subproteome in all subcellular compartments will illustrate a cellular map of this
subproteome, and would offer important novel insights.
Consequently, the primary objectives of the present investigation were to delineate the
subcellular distribution of the PKC€ signaling subproteome and to understand how assembly of
this subproteome is modulated during cardioprotection. We hereby report that the PKC€ signaling
subproteome is comprised of various multiprotein PKC€ signaling complexes; these complexes
differ in their native molecular size, and the formation of these complexes is modulated on a
subcellular basis within cardiac cells. To our knowledge, this is the first study to demonstrate the
formation of native, signaling kinase (PKCE)-based, multiprotein complexes, and to define how
modulation of these complexes directly correlates with a specific phenotype (cardioprotection).
This study provides three lines of novel information: 1) these data show differential regulation of
multiprotein complex assembly across subcellular locations, suggesting that this subcellular
organization of distinct multiprotein complexes may serve as a mechanism for signal
transduction; 2) these data demonstrate that a signaling kinase, namely PKCE, can form
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protein complexes with numerous other functionally diverse proteins, and that the distinct
molecular components of these complexes appear to be modulated in a stimulus and subcellular
location-specific manner; and most importantly, 3) these findings suggest that analysis of intact,
non-denatured multiprotein complexes is an essential step to further our understanding of the
manner in which these complexes transduce signals in normal and diseased organs.
We achieved mapping of the PKCE' subproteome using two complimentary approaches.
The first approach encompasses the biochemical methods of gel filtration, native gels, and 2D
electrophoresis, which enabled the determination of the size and composition of the protein
complexes. The data presented herein shows clearly that PKCE forms multiprotein complexes
that contain many components. Size fractionation of subcellular proteins using gel filtration
showed a dynamic size range of PKCE complexes, which differ cross subcellular compartments,
and are dynamically modulated in the non-transgenic and cardioprotected PKCE transgenic
hearts (Figure 14). Consistent with these findings, GST-PKCE pull-down and sedimentation
sucrose gradient analysis illustrate that multiprotein PKCE complexes are heterogeneous and
multimeric in nature in vivo and in vitro. Similarly, the 2D electrophoretic display of PKCE
complexes from cytosol and nuclear subcellular fractions yielded different patterns (see Figure
13c) concurrent with the hypothesiS that each subcellular fraction contains distinct PKCE
complexes.
The second approach taken was the systematic identification of proteins within individual
subcellular compartmentalized PKCE complexes, using classical immunoprecipitation and
immunoblotting techniques (Table 1 and 2). The majority of previous proteomic studies have
relied on mass spectrometry for protein identification. Indeed, using this strategy, our laboratory
has previously identified 93 proteins in the PKCE signaling subproteome (52, 142). However, in
view of the concerns of the sensitivity of our established mass spectrometry data, we have
performed a substantial amount of immunoblotting analyses to verify and substantively confirm
these results (52, 142).
The data revealed that the number and nature of specific proteins present within a PKCE
complex was dependent upon the subcellular location (see Table 1). For example, the cytosolic
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PKCE complexes contained -50 proteins from all of the functional groups (signaling, structural,
stress-activated, transcription, metabolism, and PKC binding domain). In stark contrast, the
caveolar PKCE complexes contained only 13 proteins that were primarily signaling and structural
molecules; presumably a direct reflection of the specialized nature of this particular subcellular
compartment. A somewhat surprising finding was that a large number of PKCE-associated
proteins were found outside of their normal subcellular context. The specific PKCE anchor protein
RACK2 is thought to localize to cytosolic and membranous compartments such as the
sarcolemma and Golgi (41) and indeed co-localized with PKCE in these fractions. However, it was
also found to be a key component of the mitochondrial, nuclear, and caveolar complexes. This is
an important observation, as it represents a means by which PKCE can localize to these
organelles, as has been described during cardiac protection. Similarly, we found that eNOS
interacts with PKCE in every compartment (see Figure 16). Many studies have demonstrated the
cytosolic and particularly membrane/caveolar localization of eNOS in cardiac cells (24, 180), and
thus, the interaction of eNOS with PKCE in these compartments was expected. However, eNOS
also co-localized with PKCE in the nuclear and mitochondrial fractions. Nuclear translocation of
eNOS in response to VEGF and estradiol (54) has been reported and the formation of nuclear
PKCE-eNOS complexes may allow a more direct modulation of transcription by nitric oxide. Nitric
oxide is able to permeate the mitochondrial membrane and can influence the function of many
components of oxidative phosphorylation (31). Consequently, mitochondrial PKCE-eNOS
complexes may enable PKCE to regulate myocardial energy. The functional importance of
signaling between PKCE and eNOS has been further elucidated in detail and these findings will
be presented in the subsequent Chapter. These examples show that, in addition to further
delineating the cardiac PKCE signaling system, the present study provides novel insight into the
subcellular expression of a number of molecules and therefore evidence for heretofore unknown
functions of PKCE.
The finding that the protein composition of these subcellular PKC€ complexes was
modulated during cardiac protection serves as important evidence for the role of these complexes
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to regulate phenotype. As shown in our previous study (142) many of the PKCE associated
proteins have been implicated in protection of the heart against ischemic injury cardioprotection.
To name a few, Src (146,160), Lck (144,145), Akt (39), MAPKs (12,141), COX2 (78,158), NOS
(78, 181), connexin-43 (47), NF-KB (115,181), HO-1 (184), and HIF-1 (37) have all been shown
to play protective roles in the heart. Interestingly, compartment-specific alterations in the
association of these known cardiac protective proteins within PKCf complexes were saliently
observed in the present study. For example, recruiting NF-KB to PKCE was only observed in the
nuclear fraction whereas increased binding to the caveolin-3 was only found in the caveolar
fraction. Again, these data are consistent with the specialized functions of the proteins involved:
transcription in the case of NF-KB and the structure/regulation of caveolae in the case of caveolin-

3.
In summary, the present study demonstrates that different subcellular locations within the
myocardium contain PKCE complexes with various native sizes and distinct molecular
components, suggesting that specific cellular tasks at different subcellular locations are facilitated
by regulation of these protein complexes. Furthermore, these subcellular complexes are
independently modulated in terms of size and composition when the myocardium is protected
against ischemic insult. Taken together, these findings support the notion that subcellular-specific
organization of multiprotein complexes may serve as a mechanism by which the cell controls its
phenotype.
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Figure 8. Flow chart for isolation and visualization of PKCI> multi protein signaling
complexes - experimental strategy for Chapter III Mouse hearts were homogenized

and separated into different subcellular fractions. Then gel filtration chromatography,
PKCE immunoprecipitation or GST-PKCE affinity pull down assay were applied to isolate
protein complexes. Different methods were subjected to visualize PKCE multiprotein
complexes, leading to obtain various data shown in the following figures.
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Figure 9. Two dimensional (20) electrophoresis separating

protein mixtures

obtained from mouse heart cytosolic (left) and membrane (right) subcellular
fractions. The mouse hearts were homogenized and separated into cytosolic,
membrane, mitochondrial and nuclear fractions. Subcellular extracts from cytosolic and
membrane fractions were loaded onto immobilized pH gradient (IPG) strips and
subjected to isoelectric focusing (pi) in the first dimension. The IPG strips were reequilibrated and subjected to SDS-PAGE for the second dimension by molecular weight
(MW). Proteins were then visualized by silver staining
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Figure 10. Immunoblotting analysis of known marker proteins in subcellular
fractions. Subcellular-specific marker proteins were used to verify the separation
procedure, such as nuclear-specific NuMA (upper panel); membrane-specific Na+/K+
ATPase (middle panel); and mitochondrial-specific Prohibitin-1 (lower panel). Cytosolicspecific lactate dehydrogenase (LDH) activity was also measured in each subcellular
fraction (graph).
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Figure 11. Characterization of multiprotein PKCe signaling complexes-A. Protein
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hearts

were

immunoprecipitated (IP) with PKCE antibodies, separated by 1D SDS-PAGE, and
immunoblotted (18) with PKCE antibodies. This figure showed that PKCE could be
efficiently immunoprecipitated from each subcellular fraction. Moreover, as expected that
PKCE protein expression level in every compartment were higher in PKCE transgenic
mice when compared with NTG.
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Figure

12.

Characterization

of

multiprotein

PKCe

signaling

complexes-B.

Subcellular extracts were subjected to PKCE immunoprecipitation to isolate PKCE protein
complexes. Then PKCE associated proteins were separated by 1D SDS-PAGE, and
visualized by silver staining. PKCE associated with many proteins, and the patterns of
polypeptides were significantly different in each subcellular fraction. The differences were
including the number of proteins and protein molecular weight.
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Subcellular extracts were subjected to PKCe immunoprecipitation to isolate PKCe protein
complexes. Then PKCe associated proteins were separated by 2D SDS-PAGE, and
visualized by silver staining.
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Figure 14. Demonstration of PKCE multiprotein signaling complexes by liquid
chromatography. Subcellular protein Iysates (-10mg) of both non-transgenic (NTG)
and PKCE transgenic (TG) hearts were fractionated by gel filtration. Proteins from
elution fractions were precipitated and PKCE signaling complexes visualized by
immunoblotting. All elution fractions were normalized for PKCE expression using 100/1g
NTG heart Iysates as internal control. Bar graph indicates the presence of PKCE
multiprotein complexes. The elution profiles of PKCE complexes were different in
different subcellular compartments. Compared with non-transgenic animals, the elution
profiles of PKCE complexes were shifted toward higher PKCE complexes in PKCEcardioprotective transgenic mouse hearts.
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Figure 15. Determination of the native size of multi protein PKCB complexes.

th
(a) The 120th and 180 elution fractions from the gel filtration column were
immunoprecipitated with PKCe antibodies. PKCE protein complexes were biotinylated
with a trifunctional cross-linking agent (EZ-Link Sulfo-NHS-LC-Biotin [Pierce]). The
biotinylated

proteins

were

separated

by

1D SDS-PAGE

and

visualized

by

th
immunoblotting using a streptavidin-HRP conjugate. (b) Native PAGE analysis of 180
elution fraction. Left column: various cellular multiprotein complexes visualized by
native PAGE followed by silver staining. Right column: the PKC€ protein complexes
visualized by native PAGE followed by immunoblotting (IB) for PKC€ (indicated by
arrows). (c) Sedimentation sucrose gradient analysis of GST-PKCe-associated
proteins. GST-PKCe fusion proteins were used for the affinity pull down PKC€
complexes from cytosol. Subsequently, various sizes of GST-isolated protein mixtures
were separated by sucrose gradient (10-30%). Upper panel: PKC€ immunoblotting of
the sucrose gradient fractions collected (1-to-18), arrows indicating the molecular
weight range of PKC€ multiprotein complexes (upper arrows at 232kDa and 669kDa,
respectively). Lower panel: sucrose gradient fractions (1-to-18) were further separated
by SDS PAGE and proteins visualized by silver staining.
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Figure 16. Identification of the molecular components of the multiprotein PKCE
complexes: examples of eNOS and p170 PI 3-Kinase.

Proteins from non-transgenic (NTG) and PKC£ transgenic (TG) mouse hearts were
separated into cytosolic, membrane, mitochondrial, nuclear and caveolae fractions.
Then subcellular extracts were immunoprecipitated (IP) using PKC£ antibodies,
separated by 1D SDS-PAGE and immunoblotted (18) with eNOS antibodies (left
panels) and p170 PI 3-kinase antibodies (right panels).
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Table 1 : PKCB signaling complex proteins in subcellular fractions

Mr.
(kOa)

Subcellular
Fractionations
N M Mit Cay

pi

Known Function

C

24

9.6

Contractile protein

+

Troponin T

35

5.2

Contractile protein

+

Oesmin

53

5.2

Cytoskeletal protein

+

RACK1

36

7.6

PKC binding protein

RACK2

102

5.2

PKC binding protein

+

+
+

Structural proteins
Troponin I

+
+

+

+

+

Villin

95

5.7

Cytoskeletal protein

+

W-Adaptin

106

5.0

Intracellular transport adaptor protein

+

AKAP79

79

5.1

Anchoring protein

+

+

+

Vimentin

54

5.1

Intermediate filament

+

+

+

Cadherin-2

129

4.9

Cell junction adhesions, Ca++ regulated

+

+

+

Lamin C

65

6.4

Nuclear intermediate filament

+

+

+

Cardiac development. LlM/POZ
domains

+

+

+

Oracle1/2

70/80

8.0

Vinculin

117

5.7

Focal adhesion protein

+

+

Glucose-regulated
protein

75

5.1

Molecular chaperone

+

+

Alpha-Actinin-2

104

5.4

Intermediate filament, Z band

+

+

Lap2

75

8.6

Nuclear structural protein

NMA

240

5.

Nuclear protein involved in mitosis

GM130

130

5.0

Golgi matrix protein

Prohibitin-1

30

5.6

Mitochondrial chaperone protein

Caveolin-3

18

5.5

Cardiac caveolae structural protein

Pl3-kinase

170

8.3

Phosphoinositide lipid

Pyk2

116

5.9

Lck

56

Src
PKB/Akt

+

+

+
+

+

+

+

+
+

+
+
+
+

Signaling proteins
~~inase

+

+

+

FAK tyrosine kinase family

+

+

+

5.2

Src family tyrosine kinase

+

+

+

+

60

7.9

Src family tyrosine kinase

+

+

+

+

59

5.6

Stress-activated kinase

+

+

+

+

+

+

+

+

+

+

38

5.5

Stress-activated kinase

+

JNK1/2

46/54

7.6/6.2

Stress-activated kinase

+

+

+

+

+

ERK1/2

44/42

6.0/8.9

Receptor and stress-activated kinase

+

+

+

+

+

MEK1

45

6.2

Upstream activator of ERK

+

Ras

21

6.2

GTPase that activates MAPK pathways

+

p38 MAPK

43

9.0

Cardiac gap junction protein

+

POK1

63

6.7

SerlThr kinase

+

PP2A

36

5.3

SerlThr kinase phosphatase

+

PP1

38

5.9

SerlThr kinase phosphatase

+

Connexin-43

72

+
+

+

+

+
+

+

+

+

+

+

+

+

PI-3-kinase

85

6.0

Phosphoinositide lipid kinase

+

+

+

BMX

80

8.6

Tec family tyrosine kinase

+

+

+

130

7.8

Inducible nitric oxide synthase

+

+

+

+

+
+

+

Stress-activated
proteins
iNOS
eNOS

6.6

Constitutive nitric oxide synthase

+

+

+

+

COX-2

70

7.0

Prostaglandin H synthase

+

+

+

+

Heme-oxygenase 1

32

6.1

Stress-activated protein

+

+

+

Aldose reductase

36

6.7

Osmotic stress-activated protein

+

+

Heat shock protein 70

70

5.5

Molecular chaperone

+

+

+

140

+
+

Heat shock protein 27

25

6.4

Molecular chaperone

+

+

+

aB-cystailin

20

7.3

Molecular chaperone

+

+

+

Heat shock protein 60

61

6.3

Molecular chaperone

+

+

ANT1/2

33

9.7

ATP/ADP exchanger

+

+

Creatine kinase

43

6.6

Reversibly phosphorylates creatine,
energy storage

+

GAPDH

+

Metabolism-related
proteins

36

8.4

Glycolysis

Isocitrate DH

38

6.0

Citric acid cycle

+

VDAC

31

8.6

Mitochondrial pore component (ion
transport)

+

Histone H4

14

11.3

DNA binding to facilitate chromatin
structure

+

hnRNP H1

49

5.9

mRNA processing and regulation

+

+
+

Transcription- &
Translation-Related
Proteins
+
+

hnRNP K

51

5.3

mRNA processing and regulation

+

+

Ribonucleoprotein

37

6.4

MRNA processing and regulation, heat
shock, splicing

+

+

NFKB p65

65

5.5

Activated by stress and inflammation

+

+

+

HIF-1a

100

5.2

Hypoxia-inducible transcription factor

c-Fos

55

4.8

Proto-oncogene, part of AP1 complex

+

c-Jun

36

8.9

Proto-oncogene, part of AP1 complex

+

CREB

43

5.4

Binds cAMP response element

+

Elk

45

6.3

Activated by MAPK family kinases

+

STAT 1

87

5.4

Activated by JAK family kinases
+

+

+

+

STAT3

88

5.9

Activated by JAK family kinases

c-Myc

50

5.5

Proto-oncogene

hnRNP a2/b1

37

9.0

MRNA processing and regulation

+

+

+

+

All pi values were estimated using the ExPASy compute pl/MW tool available on the web.
C=Cytosol; N=Nuclei,; M=Membrane; Mit=Mitochondria; Cav=Caveolae.
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Table 2 : Altered protein expression in PKCE signaling complex proteins in subcellular
fractions
Subcellular Fractionations
Cytosol

Nuclear

Membrane

Mitochondria

Caveolae

Structural proteins
RACK2

++

++

++

Villin
AKAP79

++

Oracle1/2

++
++

GM130

++

Caveolin-3

Signaling proteins
++

PI 3-kinase (85kDa)
Pyk2 kinase

++

Lck

++

++
++

Src
++

PKB/Akt

++
++

p38 MAPK

++

ERK1/2
++

+++

PDK1
++

BMX
PI 3-kinase (170kDa)

++

++

JNK1/2

Ras

++

++

+++
++

++

++

++

++

++

Stress-activated proteins
eNOS

++

Aldose reductase

++

Heat shock protein 27

++

++

++

++

++

++
++
++

aB-cystallin

Transcription- & TranslationRelated Proteins
NFKB p65

++

HIF-1a

++

c-Jun

++

STAT3

++

The "++" signs indicate increased expression of proteins in various subcellular compartments in
cardiac protected PKCE transgenic mice. "++" reflects a change of 1-2 fold, "+++" a change of 2-3
fold.
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CHAPTER VI
Functional proteomic analysis of myocardial PKCs-AkteNOS signaling modules during cardioprotection
Abstract
Having established in the studies described in the foregoing Chapter that PKCE complexes are
differentially regulated in a subcellular compartment specific fashion, we next wanted to
determine the manner in which individual signal transduction modules are formed to transducer
signaling within these complexes.
Among the 93 different PKCE-associated proteins that we identified to date, the protective
kinase Akt and stress-activated protein endothelial nitric oxide synthase (eNOS) are of
importance due to their independent abilities to promote cell survival and prevent cell death. Their
co-localization within the PKCE protein complex suggests that PKCE, Akt and eNOS may form
signaling modules for the regulation of nitric oxide (NO) production and hence the manifestation
of the cardioprotective phenotype. Accordingly, using functional proteomic tools, we found that:
(1) PKCE, Akt and eNOS interact and form signaling modules both in vitro and in vivo; activation
of either PKCE or Akt enhances the formation of PKCE-Akt-eNOS signaling modules; moreover,
the formation of these signaling modules is dynamically regulated during cardioprotection; (2)
PKCE directly phosphorylates and enhances activation of Akt in vitro, and PKCE transgenesis
increases both phosphorylation and activation of Akt in vivo; (3) PKCE can also directly
phosphorylate eNOS in vitro, and this phosphorylation enhances eNOS activity. Furthermore,
overexpression of PKCE in vivo increased phosphorylation of eNOS at Ser1177, representing
increased eNOS activity. This study characterizes, for the first time, functional as well as physical
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coupling of PKCE, Akt, and eNOS in the heart, and provides novel information regarding the
formation and modulation of PKCE-Akt-eNOS signaling modules during cardioprotection.
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Introduction
The proteome is proposed to be composed of multiple integrated functional subproteomes, each
of which is organized to facilitate a unique function. Moreover, specific signaling modules are
formed within these subproteomes in response to different stimuli (82, 99, 170). In particular, our
laboratory has focused on the PKCE subproteome, and the modules present within. PKCE plays a
critical role in the genesis of cardioprotection against myocardial ischemic injury (49, 75, 140,
147), and cardiac-specific expression of PKCE is cardioprotective (142). Recent studies in our
laboratory have found that PKCE forms multimeric signaling complexes with at least 93 proteins,
including structural proteins, stress-activated proteins, proteins associated with transcription and
translation, proteins involved in cellular metabolism, and various kinases and phosphatases (52,
142, 160, 172). Furthermore, the assembly of these multiprotein PKCE complexes is dynamically
modulated in PKCE-transgenic mouse hearts, which serves as important evidence for the role of
these complexes in regulating the cardioprotective phenotype. Among the 93 known protein
partners, Akt and eNOS are of great interest as they are well established to independently
promote cell survival and prevent cell death in response to various forms of stress (16, 42, 63,
182).
Previous studies in non-cardiac cells demonstrate physical and functional interactions
among PKC, Akt and eNOS. Akt can directly interact and phosphorylate eNOS on Ser1177 (63).
Akt co-immunoprecipitates with PKCI:;; or PKCt (48, 119), and the PH domain of Akt has been
implicated as the binding side for PKCI:;; to Akt1 and Akt3 (110). Li et al show that overexpression
of PKCu stimulates Akt activity and suppresses apoptosis induced by interleukin 3 withdrawals in
myeloid progenitor cells (114). In contrast, Wen and colleagues (176) report that in A549 and
HEK293 cells, the phosphatidylinositol 3-kinase/Akt signaling pathway is negatively regulated by
PKC. Moreover, it is reported that activation of PKC inhibited eNOS activity by attenuating eNOS
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phosphorylation on Ser1177 and increasing phosphorylation of Thr495 in endothelial cells (123,
124). However, despite this information nothing is known regarding the formation and regulation
of PKCE-Akt-eNOS signaling modules in myocytes, especially during cardioprotection. Therefore,
a comprehensive investigation needs to be implemented to draw a clearer picture of the temporal
and spatial relationship among PKCE, Akt and eNOS in the regulation of NO production and the
genesis of cardioprotection.
Accordingly, we hypothesized that PKCE, Akt and eNOS form a signaling module within
the mouse heart, the assembly and activation of which contributes to the genesis of
cardioprotection. By applying functional proteomic tools, we examined the PKCE-Akt-eNOS
signaling modules in vitro and in vivo in two major aspects: molecular architecture, as defined by
protein-protein interactions; and module regulation, as defined by posttranslational modification
and alteration of activity of each component of PKCE-Akt-eNOS signaling. Moreover, using mice
with cardiac-specific expression of active PKCE, we also assessed how these signaling modules
are regulated during cardioprotection.
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Results

PKCe can directly interact with Akt and eNOS in vitro
To examine the ability of PKCe to directly interact with Akt or eNOS, GST-PKCE fusion
proteins were incubated with recombinant Akt or eNOS, followed by SDS-PAGE and Western
blotting for Akt or eNOS. Figure 17 demonstrates that PKCE directly interacts with Akt in vitro.
Moreover, we also found that GST-PKCE preferentially interacts with recombinant active Akt that
is expressed by baculovirus in Sf21 insect cells and activated with GST-MAPKAPK2 and PDK1,
as compared to a much weaker interaction with inactive Akt from insect cells without treatment.
Furthermore, we assessed the domain-specificity of the interaction between Akt and PKCE by
incubating GST-PKCE with recombinant Akt protein with or without PH domain. We found that the
interaction between GST-PKCE and mutant, PH domain deficient, Akt was significantly
attenuated, suggesting that this region of Akt is responsible for its interaction with PKCE (Figure
17a and b). Taken together, our data indicated that PKCE directly interacts with Akt primarily
through binding Akt's PH domain. Using a similar approach, we also found that GST-PKCE could
also physically directly interact with eNOS, as shown in Figure 17c.
Since PKCE can directly interact with Akt and eNOS in vitro in a binary sense, we then
assessed the ability of these molecules to enhance their association with each other beyond that
seen in the foregoing pair-wise experiments. Recombinant Akt and eNOS were incubated with or
without PKCE followed by eNOS immunoprecipitation and Akt immunoblotting. We found that
recruitment of PKCE increased the binding affinity of eNOS with Akt (Figure 18a left). To examine
the effect of PKCE activity on this interaction, recombinant PKCE was next incubated with Akt and
eNOS in the presence or absence of potent PKC activators phorbol ester (PMA) and
phosphatidylserine (PS) followed by immunoprecipitation of PKCE and blotting for Akt or eNOS.
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Figure 18a (right) showed that although PKCE formed protein complexes with Akt and eNOS in
the absence of PKC activators, PMAlPS-activated PKCE exhibited a much high affinity for Akt and
eNOS, indicating that activation of PKCE enhanced its interaction with both Akt and eNOS. In
addition, we tested the effect of Akt on the interaction of PKCE and eNOS by incubating PKCE
and eNOS with active or inactive Akt recombinant proteins. Similar to the results obtained for
PKCE, activation of Akt was found to enhance its interaction with PKCE and eNOS, and its ability
to facilitate interactions between PKCE and eNOS (Figure 18b).

PKCe interacts with Akt and eNOS in vivo

Previous studies have shown that Akt and eNOS are present in cardiac PKCE-signaling
complexes,

as

assessed

by

both

GST-PKCE

affinity

pull

down

assay

and

PKCE

immunoprecipitation (52, 142), indicating that PKCE can interact with Akt and eNOS in vivo. In the
present study, using PKCE immunoprecipitation, we found that although all three isoforms of Akt
are present in the mouse heart, only Akt1 and Akt2 interact with PKCE (Data not shown).
To assess the formation of PKCE-Akt-eNOS signaling modules in vivo, mouse hearts were
homogenized and subjected to gel filtration chromatography using a Sephacryl S400 column.
This process separates intact myocardial protein complexes on the basis of their physical size.
Individual fractions from liquid chromatography were next immunoprecipitated with PKCE
antibodies. The PKCE immuno-complexes were then separated by SDS-PAGE and blotted for
PKCE, Akt and eNOS. Figure 19a shows the chromatographic profiles of PKCE-associated Akt
and eNOS protein complexes in normal mouse hearts. We found that Akt and eNOS coprecipitated with PKCE in multiple fractions, indicating that PKCE, Akt and eNOS interacted with
each other in a variety of different sized PKCE-containing complexes. Furthermore, compared
with the profiles of non-transgenic mouse hearts, we found that the expression profiles of PKCEAkt-eNOS signaling modules in PKCE-cardioprotective transgenic mice were shifted towards
higher molecular weight complexes (Figure 19b), indicating the dynamic modulation of PKCE-AkteNOS signaling modules in vivo during cardioprotection.
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PKCE can directly phosphorylate Akt and eNOS and enhance their activities in vitro.

Based on the above findings, we further investigated the effect of PKCE activation on the
formation of PKCE-Akt-eNOS modules in vitro. First, we assessed whether PKCE could directly
phosphorylate Akt and/or eNOS in vitro. Recombinant Akt or eNOS were incubated with
recombinant PKCE in the presence of the PKC activators, phorbol ester (PMA) and
phosphatidylserine

(PS),

and

radiolabeled

32

p _y_ATP.

After

SOS-PAGE

separation,

phosphorylation was visualized by autoradiography. We found that PKCE could directly
phosphorylate both Akt and eNOS (Figure 20a).
Next, we further tested the effects of these PKCE-induced phosphorylation modifications
on the activation status of Akt and eNOS. After incubating recombinant inactive Akt with PKCE,
Akt activity was assessed by its ability to phosphorylate GSK-3p. We found that Akt activation
was dramatically increased with the PKCE treatment (Figure 20b) as compared with inactive Akt
alone, indicating that activated PKCE dramatically enhances Akt activity in vitro. Similarly, we
found that PKCE treatment significantly enhanced eNOS activity, as measured by nitrate/nitrite
production, (178.8±11 %, P<0.05 vs eNOS only) when compared with non-treatment (Figure 20b).
Studies by other investigators indicate that Akt is activated by phosphorylation of Thr308
within its activation loop which serves to stabilize the molecule in its active confirmation.
Subsequently, phosphorylation of serine 473 (Ser473) at the C-terminus is essential for full
activation of Akt. While it is well known that POK1 is responsible for Thr308 phosphorylation, the
upstream kinases that catalyze the phosphorylation of Ser473 is unclear. Because our initial
studies demonstrated signal transduction between PKCE and Akt, we next tested whether PKCE
could be a putative POK2 that targets Ser473 by using the site-specific phospho-antibody of Akt
after the PKCE treatment. Figure 21 shows that addition of recombinant PKCE significantly
increased Ser473 phosphorylation on Akt as compared with that of inactive Akt alone, indicating
that in vitro, PKCE directly phosphorylates Akt on Ser473.
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PKCe transgenesis enhances phosphorylation and activation of Akt and eNOS in vivo

In addition to the in vitro phosphorylation experiments, we also examined the phosphorylation of
Akt and eNOS in vivo. PKCr::-cardioprotected transgenic mice hearts were used to test the effect
of activation of PKCe on Akt by examining the two conserved phosphorylation sites of Akt. Using
the site-specific phospho-antibodies of Akt, we found that phosphorylation of Akt on both
activation sites Thr308 (336.1±15.1% vs NTG) and Ser473 (181.3±18.2% vs NTG), was
significantly increased in PKCr:: transgenic mice when compared with non-transgenic animals.
These post-translational modification changes occurred in the absence of a total change in Akt
protein expression (Figure 22a). Interestingly, total cardiac cellular Akt activity was increased in
PKCr:: cardioprotected mice (Figure 22b top panel). Moreover, when we examined PKCr::associated Akt activity (PKCr:: complexes were isolated by immunoprecipitation and Akt kinase
activity assays performed), we found a surprising augmentation of Akt activity, considerably
greater than that seen in the total lysate pool, when Akt was associated with PKCr:: (Figure 22b
lower panel). These data support the concept that module formation between PKCr:: and Akt
accomplishes signal transduction by post-translationally modifying Akt and increasing its activity
on downstream substrates.
It is well documented that once Akt is activated, it can phosphorylate eNOS at serine
1177(Ser1177) resulting in activation of eNOS and the production of nitric oxide. Therefore, we
examined the phosphorylation of eNOS in vivo in the PKCr:: transgenic mice hearts.
Phosphorylation of eNOS on Ser1177 (407.8±43.7% vs NTG) was enhanced in the PKCr::
transgenic mice (Figure 23), indicating that overexpression of PKCr:: increased eNOS activity in

vivo. Meanwhile, total eNOS protein expression was also slightly increased (140.9±7.2% vs NTG)
in PKCr:: transgenic mice.
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Discussion
Recent studies suggest that cellular biological functions, such as signal transduction, are
accomplished by multi-protein complexes, which contain within them modules that are composed
of several species of interacting molecules. Modules may have discrete functions engendered
from the interactions among their individual components. Understanding how these molecules
interact and regulate each other is critical in order to comprehend the specific biological function
of such modules. Accordingly, in this study, we hypothesized that PKCE forms functional signaling
modules with Akt and eNOS, and that the assembly and activation of these modules contributes
to the genesis of cardioprotection. Using functional proteomic approaches, we tested the
hypothesis in two different aspects: molecular architecture and module regulation. There are
several important findings in this investigation. First, PKCE interacts with Akt and eNOS both in
vitro and in vivo, and these interactions are promoted by enhanced activation of PKCE. Second,

PKCE forms various sizes of signaling modules with Akt and eNOS, which are dynamically
regulated in PKCE transgenic mice during cardioprotection. Third, PKCE directly phosphorylates
Akt and eNOS, resulting in increased Akt and eNOS activation in vitro, whereas in vivo,
overexpression of PKCE increases both phosphorylation and activation of Akt and eNOS,
especially PKCE-associated Akt activation. This study characterizes, for the first time, physical
and functional coupling of PKCE, Akt, and eNOS in the mouse heart, and provides novel
information regarding the formation and modulation of PKCE-Akt-eNOS signaling modules during
cardioprotection.

Spatial distribution of PKCe-Akt-eNOS signaling modules

In addition to the molecular architecture of signaling modules and their regulation, the
spatial distribution of a module within the cell is another important aspect to understand the

83

function of these signaling units. Using classical immunoprecipitation and immunoblotting
techniques, our previous studies already determined the subcellular distributions of PKCE-AkteNOS signaling modules both in normal and cardioprotective hearts. We found that,
accompanying the increased protein expression of PKCE in multiple fractions (cytosol,
membrane, mitochondria, nuclear, and caveolae), protein expression of eNOS in PKCE
complexes was also increased in all five subcellular fractions. In contrast, Akt expression was
only found

to

be increased in PKCE-associated membrane and nuclear fractions in

cardioprotected mouse hearts. Therefore, although PKCE-Akt-eNOS modules were found to be
existent in multiple fractions, increased formation of this module occurred only in membrane and
nuclear fractions during cardioprotection, implicating subcellular compartment-specific functions
of PKCE-Akt-eNOS modules in normal and protected hearts. For example, many studies have
demonstrated that translocation to the membrane is an important regulatory action for activated
PKCE and Akt. Moreover, eNOS is largely membrane-associated as a result of the N-terminal
myristoylation and palmitoylation of this molecule (30). Thus, we expected to see the increased
formation of PKCE-Akt-eNOS signaling modules in membrane fractions during cardioprotection.
Increased formation of PKCE-Akt-eNOS signlaing modules in nuclear fractions in PKCE transgenic
mice may modify activation of transcription factors or other targets within nucleus fraction and
thereby regulate cardioprotective gene/protein synthesis.

PKCe forms different sizes of signaling modules with Akt and eNOS

Revealing the existence of intact, non-denatured, multiprotein PKCE-Akt-eNOS modules
is an important step to confirm our hypothesis regarding the involvement of these modules in
signal transduction. Using biochemical methods of gel filtration, PKCE immunoprecipitation, we
have delineated the physical characteristics of PKCE-Akt-eNOS signaling modules. Our data
clearly show that PKCE co-exists with Akt and eNOS in protein complexes of varying sizes in the
mouse heart. Moreover, during PKCE-induced cardioprotection, the profile of PKCE-Akt-eNOS
modules is dynamically regulated. These data provide PKCE-Akt-eNOS modules shifting to larger

84

molecular weight complexes. These data provide a solid base for our future study to explore the
composition and interaction of each PKCe-Akt-eNOS signaling module.
To confirm the presence of PKCe-Akt-eNOS signaling modules in vivo, in addition to
separation protein complexes following PKCe immunoprecipitation, we used GST-PKCe pull down
assays to form new PKCe complexes, and then separated the complexes by deoxycholatebuffered native gel electrophoresis followed by Akt and eNOS immunoblotting. It is found that
only a few of PKCe-Akt-eNOS modules had been formed in non-transgenic mouse hearts,
whereas, a high molecular weight PKCe-Akt-eNOS signaling module was found in the PKCEcardioprotected transgenic mice. The size of this macromolecular complex was estimated to be
greater than 880kDa, as determined by comparison to protein markers (data not show).
Interestingly, we found significantly fewer PKCe-Akt-eNOS modules via the native PAGE
approach as compared with the results from the gel filtration technique. The difference between
these results is most likely due to the fact that addition of exogenous PKCe will likely disrupt
endogenous preexisting complexes while also inducing formation of other complexes. Thus,
these techniques (immunoprecipitation and GST-based affinity pull-down) appear to be
complementary, in that they identify non-overlapping pools of protein interactions.
Since PKCe interacts with Akt and eNOS to form varying sizes of complexes, how do
these three molecules interact? Several investigators have shown that PH domain is the
preferred interaction domain for PKC binding to Akt. In our study, we found that PKCe preferred to
interact with Akt via its PH domain which was congruous with previous studies in non-cardiac
cells (18). Moreover, we found that PH domain of Akt may not necessary for eNOS binding to Akt
in vitro (data not shown). However, the detailed interactions among PKCe, Akt and eNOS are still

under investigation.

PKC& is a positive regulator for the formation of PKC&-Akt-eNOS Signaling modules.

Previous studies have focused on the individual roles of PKCe, Akt and eNOS as
cardioprotective proteins. These studies include one in which cardiac-specific expression of
constitutively active Akt was found to reduce infarct size and apoptosis after ischemia-reperfusion
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injury (62). In another investigation, myocardial overexpression of eNOS was found to greatly
stimulate cardiac nitric oxide production and to protect the heart against ischemia/reperfusion
injury. Despite this, the effect of PKC€ on the regulation of Akt and eNOS is controversial, and
data regarding the association of these molecules is particularly lacking in cardiac cells. Amino
acid sequence analyses reveal that both Akt and eNOS contain multiple potential PKC
phosphorylation sites. In our study, we found that PKC€ could directly phosphorylate Akt and
eNOS

in

vitro,

whereas,

cardiac-specific overexpression

of PKC€

induces

increased

phosphorylation of both Akt and eNOS.
Previous studies have shown that overexpression of PKCa stimulated the activation of
Akt. In contrast, several other investigators reported that in A549 and HEK293 cells, the
phosphatidylinositol 3-kinase/Akt signaling pathway was negatively regulated by PKC (176).
PMA-induced apoptosis was accompanied by inhibition of Akt activity (149). Similarly, PKC
activation inhibited eNOS activity by attenuating eNOS phosphorylation on Ser1177 and
increasing phosphorylation of Thr495 in cardiovascular endothelial cells (123, 124). Thus, it was
unclear in what manner PKC€, Akt and eNOS might interact to regulate each other in the setting
of cardioprotection. In the present study, cardiac PKC€ was found to serve as a positive regulator
of the formation and regulation of PKC€-Akt-eNOS signaling modules in mouse hearts. We found
that activation of PKC€ enhances the module formation, and the phosphorylation modification
induced by PKC€ may alter the conformation of both Akt and eNOS and thereby further enhance
their activity both in vitro and in vivo. These data indicate that through the increased formation of
PKC€-Akt-eNOS Signaling modules, activation of PKC€ may promote cell survival and stimulate
nitric oxide synthesis, and therefore contribute to the genesis of cardioprotection against ischemic
injury.
Regarding the finding that PKC€ can directly phosphorylate eNOS and increase eNOS
activity in vitro, the possibility exists that the purity of eNOS recombinant protein may influence
the in vitro results. Nonetheless, the increased eNOS activity appear to be PKC€-dependent.
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PKCe is

a candidate for PDK2

Akt has two conserved phosphorylation sites, Thr30S, and Ser473, which are necessary for its
maximum activation. Generally, the upstream kinase that fulfils the phosphorylation of Thr30S is
PDK-1. But the upstream kinases that are responsible for the Ser473 phosphorylation is
unknown, and has been tentatively named "PDK-2". Several candidates have been proposed,

s

including PKC (34 ,190), a lipid-raft-associated kinase (S4), or simply the autophosphorylation
processes followed by the PDK-1 activity (1). In the present study, we tested the hypothesis that
PKCE may exhibit PDK-2 activity by phosphorylating Akt Ser473. Interestingly, we found that
PKCE did indeed phosphorylate Akt Ser473 in vitro, indicating PKCE maybe one of the candidates
in vivo to target Akt and increase Akt activation by modifying Ser473 phosphorylation.

Determination of the ability of PKCE to phosphorylate Akt on Ser473 in vivo, and the physiological
importance of this post-translational modification is an extensive process that is beyond the scope
of the current investigation.
In summary, this study successfully characterized myocardial PKCE-Akt-eNOS signaling
modules, which can serve as a good model for future research addressing the signaling
mechanisms underlying PKCE-mediated cardioprotection and other phenotypes. The present
study provided new information about the molecular architecture of PKCE-Akt-eNOS signaling
modules, the subcellular localization of these modules, and the dynamic modulation of these
modules during the development of the cardioprotective phenotype. These studies are critical
steps towards our goal of defining the cardiac proteome, the multiple integrated functional
subproteomes that compose this proteome, and the specific signaling modules required for
unique cellular functions.
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Figure 17. PKCe directly interacts with Akt and eNOS in vitro GST-PKCE fusion

proteins were incubated with recombinant Akt or eNOS, followed by SDS-PAGE and
Western blotting for Akt or eNOS. a. GST-PKCE interacts with Akt in vitro, and
preferentially interacts with recombinant active Akt when compared with recombinant
inactive Akt; b. GST-PKCE had higher binding affinity with the Akt PH domain when
compared with PH domain deleted Akt; c. GST-PKCE also physically interacts with
eNOS in vitro.
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Figure 18. Activation of both PKCe and Akt enhanced PKCe-Akt-eNOS module
formation in vitro. a. Left, recombinant Akt and eNOS were incubated with or without
PKCe followed by eNOS immunoprecipitation and Akt immunoblotting. Recruitment of
PKCE increased the binding affinity of eNOS with Akt; right, recombinant PKCE was
further incubated with Akt and eNOS plus or minus potent PKC activators phorbol ester
(PMA) and phosphatidylserine (PS) followed by immunoprecipitation of PKCE and blotting
for Akt or eNOS. PMAlPS-activated PKCE exhibited higher affinity for Akt and eNOS
compared with that of PKCE without stimulation. b PKCE and eNOS with active or inactive
Akt recombinant proteins. Activation of Akt also enhanced the interaction of PKCE with
Akt and eNOS.
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Figure 19. Formation of PKCe-Akt-eNOS signaling modules in vivo. Mouse hearts
were homogenized and subjected to gel filtration chromatography using a Sephacryl
S400 column followed by immunoprecipitation with PKCE antibodies and immunoblotting
for PKCE, Akt and eNOS. a. The chromatographic profiles of PKCE-associated Akt and
eNOS protein complexes in the normal mouse hearts; b the chromatographic profiles of
PKCE-associated Akt and eNOS protein complexes in the PKCE-transgenic mouse
hearts. Akt and eNOS co-precipitated with PKCE in multiple fractions to form a variety of
different sized PKCE complexes. Compared with the profiles of non-transgenic mouse
hearts, the expression profiles of PKCE-Akt-eNOS signaling modules in PKCEcardioprotective transgenic mice were shifted towards
complexes.
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a. Recombinant Akt or eNOS incubated with recombinant PKCE in the presence of the
32

PKC activators phorbol ester (PMA) and phosphatidylserine (PS) and p _y_ATP. After
SOS-PAGE separation, phosphorylation was visualized by autoradiography; b. After
incubating recombinant inactive Akt or eNOS with PKCE, Akt and eNOS activity were
assessed by its ability to phosphorylate

GSK-3~
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or produce nitrate/nitrite, respectively.
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Figure 21. PKCE directly phosphorylated Akt at its Ser473 site in vitro. After
incubating PKCE with recombinant Akt, Ser473 phosphorylation was detected by site473

specific antibody phospho-Akt-Ser

.

Addition of recombinant PKCE significantly

increased Ser473 phosphorylation on Akt as compared with that of inactive Akt alone.
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Figure 22. Effect of PKCe on the phosphorylation and activation of Akt in
vivo

a. Non-transgenic and PKCf: transgenic mouse hearts were homogenized, and
separated with SDS-PAGE followed by immunoblotting with Akt, PKCE and sitespecific phospho-Akt antibodies. Compared with non-transgenic animals,
phosphorylation of Akt on its activation sites Thr-308 and Ser-473 was
significantly increased in cardioprotective PKCE transgenic mice; b. Total Akt
activity and PKCE-associated Akt activity was measured by its ability to
phosphorylate

GSK-3~.

Total cardiac cellular Akt activity was increased in PKCE

cardioprotected mice when compared with non-transgenic mice. Moreover,
PKCE-associated Akt activity had greater elevation when compared with the
increase in the total lysate pool.
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Figure 23. Effect of PKCe on the phosphorylation of eNOS in vivo. Non-transgenic
and PKCe transgenic mouse hearts were homogenized and separated with SDS-PAGE
followed by immunoblotting with the eNOS and site-specific phospho-eNOS Ser

1177

antibodies. Compared with non-transgenic animals, phosphorylation of eNOS on serine1177, the Akt-specific activation site, was also enhanced in the PKCe transgenic mice.

100

% of NTG
~

a

a
a

a'"
a

'"aa

..,.

'"aa

a
a

1

,

Z

-l

(j)

I,
"

I
"1l

A

()

*

Z

-l

(j)

I

t

"1l

A

()

co
-l

co
-l

*

(j)

• 0

"0
A

a 0 :,0
0 Q!.
'"
CD "0
< Z :,-

'"
'"Z o
--I

(j)

G)"O

S

"

~

It

~

-I "0

aro

s·

9

~

0

(j)
(j)

CD

'":::

~

ct>

z

0

(f)

"1l

::T

0

'"0

"0
::T

,

ct>

z

0

(f)

(f)

ct>

'~

~
~

101

(j)

REFERENCES
1.

Adams JA. Kinetic and catalytic mechanisms of protein kinases Chern Rev
101 :2271-2290,2001.

2.

Akita Y. Protein kinase C-e (PKCe): its unique structure and function. J Biochern.
132: 847-852, 2002.

3.

Alberts B. The cell as a collection of protein machines: preparing the next
generation of molecular biologists. Cell 92:291-294, 1998.

4.

Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure,
function and inhibition. Biochern J 357:593-615, 2001.

5.

Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen
P. Characterization of a 3-phosphoinositide-dependent protein kinase which
phosphorylates and activates protein kinase Balpha. Curr Bioi 7:261-269, 1997.

6.

Allen NP, Huang L, Burlingame A, Rexach M. Proteomic analysis of nucleoporin
interacting proteins. J Bioi. Chern. 276:29268-29274, 2001.

7.

Altomare DA, Guo K, Cheng JQ, Sonoda G, Walsh K, Testa JR. Cloning,
chromosomal localization and expression analysis of the mouse Akt2 oncogene.
Oncogene 11 :1055-1060, 1995.

8.

Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, Cron P,
Cohen P, Lucocq JM, Hemmings BA. Role of translocation in the activation and
function of protein kinase B. J Bioi Chern 272:31515-31524,2001.

9.

Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc
Res 43: 521-531, 1999.

10.

Armour KE, Armour KJ, Gallagher ME. Defective bone formation and anabolic
response to exogenous estrogen in mice with targeted disruption of endothelial
nitric oxide synthase. Endocrinology 142: 760-766, 2001.

11.

Cohen MV, Baines CP, Downey JM. Ischemic preconditioning: from adenosine
receptor of KATP channel. Annu Rev Physiol. 62:79-109, 2000.

12.

Baines CP, Zhang J, Wang GW, Zheng YT, Xiu JX, Cardwell EM, Bolli R, Ping P.
Mitochondrial PKCepsilon and MAPK form signaling modules in the murine heart:
enhanced mitochondrial PKCepsilon-MAPK interactions and differential MAPK
activation in PKCepsilon-induced cardioprotection.Circ Res .90:390-397, 2002.

13.

Ballif BA, Shimamura A, Pae E, Blenis J. Disruption of 3-phosphoinositidedependent kinase 1 (PDK1) signaling by the anti-tumorigenic and antiproliferative agent n-alpha-tosyl-I-phenylalanyl chloromethyl ketone. J Bioi Chern
276:12466-12475,2001.

102

14.

Balligand JL, Kobzik L, Han X, et al. Nitric oxide-dependent parasympathetic signaling is
due to activation of constitutive endothelial (type III) nitric oxide synthase in cardiac
myocytes. J Bioi Chern 1995; 270: 14852-14856. Biochern J 299: 247-252,1994.

15.

Belevych AE, Harvey RD .. Muscarinic inhibitory and stimulatory regulation of the L-type
2
Ca + current is not altered in cardiac ventricular myocytes from mice lacking endothelial
nitric oxide synthase. J Physiol. 528 :279-289, 2000.

16.

Bell RM, Yellon DM. Bradykinin limits infarction when administered as an adjunct to
reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol 35:185193,2003.

17.

Bell AW, Ward MA, Blackstock WP, Freeman HN, Choudhary JS, Lewis AP, Chotai D,
Fazel A, Gushue IN, Paiement J, Palcy S, Chevet E. Lafreniere-Roula, M., Solari, R.,
Thomas, D.Y,. Rowley, A., Bergeron, J.J. Proteomics characterization of abundant Golgi
membrane proteins. J Bioi Chern. 276, 5152-516, 2001.

18.

Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D, McCormick F, Feng
J, Tsichlis P. Akt activation by growth factors is a multiple-step process: the role of the
PH domain. Oncogene 17:313-325,1998.

19.

Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a
serine-threonine kinase containing an SH2-like region. Science 11 ;254:274-277, 1999.

20.

Benjamin IJ, McMillan DR. Stress (heat shock) proteins: molecular chaperones in
cardiovascular biology and disease. Circ Res 83: 117 -132, 1998.

21.

Bernardo NL, D'Angelo M, Okubo S, Joy A, Kukreja RC. Delayed ischemic
preconditioning is mediated by opening of ATP-sensitive potassium channels in the rabbit
heart. Arn J Physiol 276:H1323-1330, 1999.

22.

Berry DA, Keogh A, Dos Remedios eG. Nuclear membrane proteins in failing human
dilated cardiomyopathy. Proteornics. 1: 1507-1512, 2001.

23.

Bolli R. The late phase of preconditioning. Circ Res. 87:972-983, 2002.

24.

Brahmajothi MV, Campbell DL. Heterogeneous basal expression of nitric oxide synthase
and superoxide dismutase isoforms in mammalian heart : implications for mechanisms
governing indirect and direct nitric oxide-related effects. Circ Res. 85, 575-587, 1999.

25.

Braunwald, Zipes, Libby. Heart disease: a textbook of cardiovascular medicine 6 edition.
2001.

26.

Brazil DP, Hemmings BA. Ten years of protein kinase B signaling: a hard Akt to follow.
Trends Biochern Sci 26:657-664,2001.

27.

Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neural
role for nitric oxide. Nature 347: 768-770,1990.

28.

Brunet A, Datta SR, Greenberg ME. Transcription-dependent and -independent control of
neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 11 :297-305,
2001.

th

103

29.

Brunner F, Maier R, Andrew P, Wolkart G, Zechner R, Mayer B. Attenuation of
myocardial ischemialreperfusion injury in mice with myocyte-specific overexpression of
endothelial nitric oxide synthase. Cardiovasc Res 57:55-62, 2003.

30.

Busconi L, Michel T. Endothelial nitric oxide synthase: N-terminal myristoylation
determines subcellular localization. J BioI Chern 268: 8410-8413, 1993.

31.

Bustamante J, Bersier G, Badin RA, Cymeryng C, Parodi A, Boveris A Sequential NO
production by mitochondria and endoplasmic reticulum during induced apoptosis. Nitric
Oxide 6: 333-341, 2002.

32.

Castrillo A, Pennington OJ, Otto F, Parker PJ, Owen MJ, Bosca L. Protein kinase C
epsilon is required for macrophage activation and defense against bacterial infection. J.
Exp. Med. 194:1231-1242,2001.

33.

Cenni V, Doppler H, Sonnenburg ED, Maraldi N, Newwton AC, Toker A Regulation of
novel protein kinase C epsilon by phosphorylation. Biochern. J. 363:537-545, 2002.

34.

Chan TO, Tsichlis PN. PDK2: A complex tail in one Akt. Sci STKE. 23;(66):PE1, 2001.

35.

Chen R, Kim 0, Yang J, Sato K, Eisenmann KM, McCarthy J, Chen H, Qiu Y. Regulation
of AktJPKB activation by tyrosine phosphorylation. J BioI Chern 276:31858-31862, 2001.

36.

Chen J, Rappsilber J, Chiang YC, Russell P, Mann M, Denis CL. Purification and
characterization of the 1.0 MDa CCR4-NOT complex identifies two novel components of
the complex. J Mol BioI 314:683-694,2001.

37.

Chilov 0, Camenisch G, Kvietikova I, Ziegler U, Gassmann M, Wenger RH. Induction and
nuclear translocation of hypoxia-inducible factor-1 (HIF-1): heterodimerization with ARNT
is not necessary for nuclear accumulation of HIF-1alpha. J Cell Sci. 112:1203-1212,
1999.

38.

Coffer PJ, Woodgett JR. Molecular cloning and characterization of a novel putative
protein-serine kinase related to the cAMP-dependent and protein kinase C families Eur J
Biochern 201 :475-481,1991.

39.

Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R, laccarino G, Russo MA, Gu
Y, Dalton N, Chung C, Latronico MV, Napoli C, Sadoshima J, Croce CM, Ross J Jr. Akt
induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc
Natl Acad Sci U.S.A. 99:12333-12338,2002.

40.

Cook SA, Matsui T, Li L, Rosenzweig A Transcriptional effects of chronic Akt activation
in the heart. J BioI Chern. 277:22528-22533, 2002.

41.

Csukai M, Chen CH., De Matteis MA, Mochly-Rosen D. The coatomer protein beta'COP, a selective binding protein (RACK) for protein kinase Cepsilon. J BioI Chern.
272:29200-29206,1997.

42.

Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev
13:2905-2927, 1999.

43.

Davda RK, Chandler LJ, and Guzman NJ. Protein kinase C modulates receptorindependent activation of endothelial nitric oxide synthase. Eur J Pharmacal 266:237244, 1994.

104

44.

Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric
oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399:601605,1999.

45.

Dinerman JL, Dawson TM, Schell MJ, Snowman A, Snyder SH. Endothelial nitric oxide
synthase localized to hippocampal pyramidal cells: implications for synaptic plasticity.
Proc Natl Acad Sci U.S.A. 91: 4214-4218,1994.

46.

Ding L, Wang H, Lang W, Xiao L. Protein kinase C-epsilon promotes survival of lung
cancer cells by suppressing apoptosis through dysregulation of the mitochondrial
caspase pathway. J BioI Chem 277:35305-35313,2002.

47.

Doble BW, Ping P, Kardami E. The epsilon subtype of protein kinase C is required for
cardiomyocyte connexin-43 phosphorylation. Circ Res. 86, 293-301, 2000.

48.

Doornbos RP, Theelen M, van der Hoeven PC, van Blitterswijk WJ, Verkleij AJ, van
Bergen en Henegouwen PM. Protein kinase C zeta is a negative regulator of protein
kinase B activity. J BioI Chem 274:8589-8596,1999.

49.

Dorn 2 GW, Souroujon MC, Liron T, Chen C-H, Gray MO, Zhou HZ, Csukai M, Wu G,
Lorenz IN, Mochly-Rosen D. Sustained in vivo cardiac protection by a rationally designed
peptide that causes E protein kinase C translocation. Proc Nat! Acad Sci USA 96:1279812803, 1999.

50.

Dorn G.w., 2nd, Mochly-Rosen, D. Intracellular transport mechanisms of signal
transducers. Annu. Rev. Physiol. 64: 407-429, 2002.

51.

Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits
endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J
Clin Invest 108:1341-1348,2002.

52.

Edmondson RD, Vondriska TM, Biedermant K, Zhang J, Jones R, Zheng YT, Allen DL,
Xiu JX, Cardwell EM, Pisano MR, Ping P. Protein kinase C epsilon signaling complexes
include metabolism- and transcription/translation-related proteins: complimentary
separation techniques with LC/MS/MS. Molecular Cellular Proteomics. 6:421-433, 2002.

53.

Faller DV. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol.
26:74-84,1999.

54.

Feng Y, Venema VJ, Venema RC, Tsai N, Caldwell RB. VEGF induces nuclear
translocation of Flk-1/KDR, endothelial nitric oxide synthase, and caveolin-1 in vascular
endothelial cells Biochem Biophys Res Commun 256:192-197,1999.

55.

Fisslthaler B, Dimmeler S, Hermann C, Busse R, and Fleming I. Phosphorylation and
activation of the endothelial nitric oxide synthase by fluid shear stress. Acta Physiol
Scand. 168: 81-88, 2000.

56.

Fleming I, Busse R. Signal transduction of eNOS activation. Cardiovasc Res. 15;43:532541,1999.

57.

Fleming I, Bauersachs J, Fisslthaler B, and Busse R. Ca +-independent activation of the
endothelial nitric oxide synthase in response to tyrosine phosphatase inhibitors and fluid
shear stress. Cire Res. 82: 686-695, 1998.

nd

2

105

58.

Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, and Busse R. Phosphorylation of Thr495
2
regulate Ca +/calmodulin- dependent endothelial nitric oxide synthase activity. Circ Res
88:68-75,2001

59.

Flynn P, Wongdagger M, Zavar M, Dean NM, Stokoe D. Inhibition of PDK-1 activity
causes a reduction in cell proliferation and survival. Curr BioI 10:1439-1442, 2002.

60.

Fontana J, Fulton 0, Chen Y, Fairchild TA, McCabe TJ, Fujita N, Tsuruo T, Sessa WC.
Domain mapping studies reveal that the M domain of hsp90 serves as a molecular
scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase
and NO release. Circ Res 90:866-873, 2002.

61.

Fraser 10, Cong M, Kim J, Rollins EN, Daaka Y, Lefkowitz RJ, Scott JD. Assembly of an
A-kinase-anchoring protein-P2-adrenergic receptor complex facilitates receptor
phosphorylation and signaling. Curr BioI 10:409-412, 2001.

62.

Fujio Y, Nguyen T, Wencker 0, Kitsis RN, Walsh K. Akt promotes survival of
cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart
Circulation 101 :660-667, 2001.

63.

Fulton 0, Gratton JP, McCabe T J, Fontana J, Fujio Y, Walsh K, Franke TF,
Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production
by the protein kinase Akt. Nature 399:597-601, 1999.

64.

Gallis B, Corthals GL, Goodlett DR, Ueba H, Kim F, Presnell SR, Figeys 0, Harrison DG,
Berk BC, Aebersold R, and Corson MA. Identification of flow-dependent endothelial nitric
oxide synthase phosphorylation sites by mass spectrometry and regulation of
phosphorylation and nitric oxide production by the phosphatidylinositol 3-kinase inhibitor
LY294002. J BioI Chern 274: 30101-30108,1999.

65.

Garcia-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G, Papapetropoulos A, Sessa
WC. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 392:821824,1998.

66.

Gavin AC, Bosche M, Krause R, Grandi P, Marzioch M, Bauer A, Schultz J, Rick JM,
Michon AM, Cruciat CM, Remor M, Hofert C, Scheider M, Brajenovic M, Ruffner H,
Merino A, Klein K, Hudak M, Dickson 0, Rudi T, Gnau V, Bauch A, Bastuck S, Huhse B,
Leutwein C, Heurtier MA, Copley RR, Edelmann A, Querfurth E, Rybin V, Drewes G,
Raida M, Bouwmeester T, Bork P, Seraphin B, Kuster B, Neubauer G, Superti-Furga G.
Functional organization of the yeast proteome by systematic analysis of protein
complexes. Nature 415:141-147,2002.

67.

Gerber HP, McMurtrey A, Kowalski J, Van M, Keyt BA, Dixit V, Ferrara N. Vascular
endothelial growth factor regulates endothelial cell survival through the
phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk1/KDR activation. J BioI Chern 273:30336-30343,1998.

68.

Gilliam MB, Sherman MP, Griscavage JM, Ignarro LJ. A spectrophotometric assay for
nitrate using NADPH oxidation by Aspergillus nitrate reductase. Anal Biochern. 212:359365,1993.

69.

Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold
R, Sonenberg N. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism.
Genes Dev 13:1422-37,1999.

106

70.

Godecke A, Heinicke T, Kamkin A, Kiseleva I, Strasser RH, Decking UK, Stumpe T,
Isenberg G, Schrader J. Godecke A, Heinicke T, Kamkin A, Kiseleva I, Strasser RH,
Decking UK, Stumpe T, Isenberg G, Schrader J. Inotropic response to beta-adrenergic
receptor stimulation and anti-adrenergic effect of ACh in endothelial NO synthasedeficient mouse hearts. J Physiol. 532:195-204, 2001.

71.

Godovac-Zimmermann J, Soskic V, Poznanovic S, Brianza F. Functional proteomics of
signal transduction by membrane receptors. Electrophoresis 20: 952-961, 1999.

72.

Graness A, Adomeit A, Heinze R, Wetzker R, Liebmann C. A novel mitogenic signaling
pathway of bradykinin in the human colon carcinoma cell line SW-480 involves sequential
activation of a Gq/11 protein, phosphatidylinositol 3-kinase beta, and protein kinase C
epsilon. J. BioI. Chern. 273:32016-32022,1998.

73.

Graves PR, Haystead TA. A functional proteomics approach to signal transduction.
Recent Prog Horm Res. 58:1-24,2003.

74.

Gravin AC. Functional organization of the yeast proteome by systematic analysis of
protein complexes. Nature. 415:141-147, 2002.

75.

Gray MO, Karliner JS, Mochly-Rosen D. A selective E-protein kinase C antagonist inhibits
protection of cardiac myocytes from hypoxia-induced cell death. J BioI Chern 272: 3094530953,1997.

76.

Gross SS, Wolin MS. Nitric oxide: pathophysiological mechanisms. Annu Rev Physio/57:
737-769,1995.

77.

Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX results in its
translocation, mitochondrial dysfunction and apoptosis. EMBO J 171 :3878-3885, 1998.

78.

Guo Y, Jones WK, Xua YT, Tang XL, Bao W, Wu WJ, Han H, Laubach VE, Ping P, Yang
Z, Qiu Y, Bolli R. The late phase of ischemic preconditioning is abrogated by targeted
disruption of the inducible NO synthase gene. Proc Nat! Acad Sci USA 96:1150711512,1999.

79.

Gyurko R, Kuhlencordt P, Fishman MC, Huang PL. Modulation of mouse cardiac function
in vivo by eNOS and ANP. Am J Physio/278:H971-981, 2000.

80.

Hare JM, Lofthouse RA, Juang GJ, Colman L, Ricker KM, Kim B, Senzaki H, Cao S,
Tunin RS, Kass DA. Contribution of caveolin protein abundance to augmented nitric
oxide Signaling in conscious dogs with pacing-induced heart failure. Circ Res. 86:10851092,2000.

81.

Harrison PM, Kumar A, Lang N, Snyder M, Gerstein M. A question of size: the eukaryotic
proteome and the problem in defining it. Nucleic Acids Res. 30: 1083-1090,2002.

82.

Hartwell LH, Hopfield JJ, Leibler S, Murry AW. From molecular to modular cell biology
Nature (Supp). 402:C47-C52, 1999.

83.

Hemmens B, Mayer B. Enzymology of nitric oxide synthases. Methods Mol BioI 100:1-32,
1998.

84.

Hill MM, Feng J, Hemmings SA. Identification of a plasma membrane Raft-associated
PKB Ser473 kinase activity that is distinct from ILK and PDK1. Curr BioI 12:1251-1255,
2002.

107

85.

Hirata K, Kuroda R, Sakoda T, Katayama M, Inoue N, Suematsu M, Kawashima S, and
Yokoyama M. Inhibition of endothelial nitric oxide synthase activity by protein kinase C.
Hypertension. 25:180-185,1995.

86.

Ho Y, Ho Y, Gruhler A, Heilbut A, Bader GD, Moore L, Adams SL, Millar A, Taylor P,
Bennett K, Boutilier K, Yang L, Wolting C, Donaldson I, Schandorff S, Shewnarane J, Vo
M, Taggart J, Goudreault M, Muskat B, Alfarano C, Dewar D, Lin Z, Michalickova K,
Willems AR, Sassi H, Nielsen PA, Rasmussen KJ, Andersen JR, Johansen LE, Hansen
LH, Jespersen H, Podtelejnikov A, Nielsen E, Crawford J, Poulsen V, Sorensen BD,
Matthiesen J, Hendrickson RC, Gleeson F, Pawson T, Moran MF, Durocher D, Mann M,
Hogue CW, Figeys D, Tyers M. Systematic identification of protein complexes in
Saccharomyces cerevisiae by mass spectrometry. Nature 415:180-183,2002.

87.

Hoang VM, Foulk R, Clauser K, Burlingame A, Gibson BW, Fisher SJ. Functional
proteomics: examining the effects of hypoxia on the cytotrophoblast protein repertoire.
Biochemistry 40:4077-4086,2001.

88.

Hodgkinson CP, Sale EM, Sale GJ. Characterization of PDK2 activity against protein
kinase B gamma. Biochemistry 41:10351-10359,2002.

89.

Hoffman A, Gloe T, Pohl U. Hypoxia-induced upregulation of eNOS gene expression is
redox-sensitive: a comparison between hypoxia and inhibitors of cell metabolism. J Cell
Physiol. 188: 33-44, 1998.

90.

Hoffmann P, Ji H, Moritz RL, Connolly LM, Frecklington DF, Layton MJ, Eddes JS,
Simpson RJ. Continuous free-flow electrophoresis separation of cytosolic proteins from
the human colon carcinoma cell line LIM 1215: a non two-dimensional gel
electrophoresis-based proteome analysis strategy. Proteomics 1:807 -818, 2001.

91.

Hondermarck H, Vercoutter-Edouart AS, Revillion F, Lemoine J, EI-Yazidi-Belkoura I,
Nurcombe V, Peyrat JP. Proteomics of breast cancer for marker discovery and signal
pathway profiling. Proteomics. 1:1216-1232,2001.

92.

Huang PL. Mouse models of nitric oxide synthase deficiency. J Am Soc Nephrol
16:S120-123,2000.

93.

Huang C, Zhou Q, Liang P, Hollander MS., Sheikh F, Li X, Greaser M, Shelton GD,
Evans S, Chen J. Characterization and in vivo functional analysis of splice variants of
Cypher. J BioI Chem. 278:7360-7365, 2003.

94.

Hubbard MJ, Cohen P. On target with a new mechanism for the regulation of protein
phosphorylation. Trends Biochem Sci 18:172-177,1993.

95.

Huber LA, Pfaller K, Vietor I. Organelle Proteomics Implication for subcellular fraction in
proteomics. Circ. Res. 92: 962-968, 2003.

96.

Huber LA. Opinion: is proteomics heading in the wrong direction? Nat Rev Mol Cell BioI.
4: 74-80, 2003.

97.

Hunter T. Signaling--2000 and beyond. Cell 100: 113-127,2000.

98.

Husi H, Grant SG. Isolation of 200-kDa complexes of NMDA receptor and postsynaptic
density 95 from mouse brain. J Neurochem 277:281-291, 2001.

99.

Husi H, Ward MA, Choudhary JS, Blackstock WP, Grant SG. Proteomic analysis of
NMDA receptor-adhesion protein signaling complexes. Nat Neurosci. 3:661-669, 2000.

108

100.

Jones PF, Jakubowicz T, Pitossi FJ, Maurer F, Hemmings BA. Molecular cloning and
identification of a serine/threonine protein kinase of the second-messenger subfamily.
Proc Nat! Acad Sci U.S.A. 88:4171-4175,1991.

101.

Jordan JD, Landau EM, Iyengar R. Signaling networks: the origins of cellular
multitasking. Cell 103: 193-200, 2000.

102.

Ju H, Venema VJ, Marrero MB, Venema RC. Inhibitory interactions of the bradykinin B2
receptor with endothelial nitric-oxide synthase. J BioI Chem. 273:24025-24029, 1998.

103.

Kandel ES, Hay N. The regulation and activities of the multifunctional serine/threonine
kinase AktlPKB. Exp Cell Res 253:210-29, 1999.

104.

Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF-kappaB by the AktlPKB
kinase. Curr BioI 9:601-4, 1999.

105.

Kelly RA, Balligand JL, Smith TW. Nitric oxide and cardiac function. Circ Res 79:363-80,
1996.

106.

Khasar SG, Lin YH, Martin A, Dadgar J, McMahon T, Wang D, Hundle B, Aley KO,
Isenberg W, McCarter G, Green PG, Hodge CW, Levine JD, Messing RO. A novel
nociceptor signaling pathway revealed in protein kinase C epsilon mutant mice. Neuron
24:253-260,1999.

107.

Kim F, Gallis B, and Corson MA. TNF inhibits flow and insulin signaling leading to NO
production in aortic endothelial cells. Am J Physiol Cell Physiol 280: C1057-C1065,
2001.

108.

Klatt P, Pfeiffer S, List BM, et al. Characterization of the heme-deficient neuronal nitric
oxide synthase reveals a role for heme in subunit dimerization and binding of the amino
acid substrate and tetrahydrobiopterin. J BioI Chern. 271: 7336-7342, 1996.

109.

Knezevic V, Leethanakul C, Bichsel VE, Worth JM, Prabhu W, Gutkind JS, Liotta LA,
Munson PJ, Petricoin EF. 3rd, Krizman DB. Proteomic profiling of the cancer
microenvironment by antibody arrays. Proteomics 1:1271-1278, 2001.

110.

Konoshi H, Kuroda S, Tanaka M, Matsuzaki H, Ono Y, Kameyama K, Haga T, Kikkawa
U. Molecular cloning and characterization of a new member of the RAC protein kinase
family: Association of the pleckstrin homology domain of three types of RAC protein
kinase with protein kinase C subspecies and beta gamma subunits of G proteins.
Biochem Biophys. Res. Commun. 216: 526-534,1995.

111.

Lantinhermoso RL, Rosenfeld CR, Yuhanna IS, German Z, Chen Z, and Shaul PW.
Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery
endothelium. Am J. Physiol. 274:R797-807, 1998.

112.

Lehel C, Olah Z, Jakab G, Szallasi Z, Petrovics G, Harta G, Blumberg PM, Anderson WB.
Protein kinase C epsilon subcellular localization domains and proteolytic degradation
sites. A model for protein kinase C conformational changes. J. BioI. Chern. 270: 1965119658, 1995.

113.

Lewis TS, Hunt JB, Aveline LD, Jonscher KR, Louie DF, Yeh JM, Nahreini TS, Resing
KA, Ahn NG. Identification of novel MAP kinase pathway signaling targets by functional
proteomics and mass spectrometry. Mol Cell 6:1343-1354,2000.

109

114.

Li W, Zhang J, Flechner L, Hyun T, Yam A, Franke TF, Pierce JH Protein kinase C-alpha
overexpression stimulates Akt activity and suppresses apoptosis induced by interleukin 3
withdrawal. Oncogene 18:6564-6572, 1999.

115.

Li RC, Ping P, Zhang J, Wead WB, Cao X, Gao J, Zheng Y, Huang S, Han J, Bolli R.
PKCepsilon modulates NF-kappaB and AP-1 via mitogen-activated protein kinases in
adult rabbit cardiomyocytes. Am J Physiol. 279:H1679-1689, 2000.

116.

List BM, Klosch B, Volker C. Characterization of bovine endothelial nitric oxide synthase
as a homodimer with down-regulated uncoupled NADPH oxidase activity:
tetrahydrobiopterin binding kinetics and role of haem in dimerization. Biochem J
323:159-165,1997.

117.

Liu GS, Cohen MV, Mochly-Rosen D, Downey JM. Protein kinase CE is responsible for
the protection of preconditioning in rabbit cardiomyocytes. J Mol Cell Cardio/31:19371948,1999.

118.

Lopez MF, Melov S. Applied proteomics: mitochondrial proteins and effect on function.
Circ Res. 90:380-389,2002.

119.

Mao M, Fang X, Lu Y, Lapushin R, Bast RC Jr, Mills GB. Inhibition of growth-factorinduced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase
C in breast cancer cells. Biochem J. 352:475-478,2002.

120.

Matsubara M, Titani K, and Taniguchi H. Interaction of calmodulin-binding domain
peptides of nitric oxide synthase with membrane phospholipids: regulation by protein
phosphorylation and Ca 2+-calmodulin. Biochemistry 35: 14651-14658, 1996.

121.

Matsui T, Tao J, del Monte F, Lee KH, Li L, Picard M, Force TL, Franke TF, Hajjar RJ,
Rosenzweig A. Akt activation preserves cardiac function and prevents injury after
transient cardiac ischemia in vivo. Circulation 104:330-335, 2001.

122.

McQuillan LP, Leung GK, Marsden PA, Kostyk SK, and Kourembanas S. Hypoxia inhibits
expression of eNOS via transcriptional and posttranscriptional mechanisms. Am J Physiol
267: H1921-1927, 1994.

123.

Michell BJ, Chen ZP, Tiganis T, Stapleton D, Katsis F, Power DA, Sim AT, Kemp BE.
Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase
C and the cAMP-dependent protein kinase. J BioI Chem 276: 17625-17628, 2001.

124.

Michell BJ, Griffiths JE, Mitchelhill KI, Rodriguez-Crespo I, Tiganis T, Bozinovski S, de
Montellano PR, Kemp BE, Pearson RB. The Akt kinase signals directly to endothelial
nitric oxide synthase. Curr BioI. 9:845-848, 1999.

125.

Mohamed F, Monge JC, Gordon A, Cernacek P, Blais D, and Stewart DJ. Lack of role for
nitric oxide (NO) in the selective destabilization of endothelial NO synthase mRNA by
tumor necrosis factor-alpha. Arterioscler Thromb Vasc BioI 15: 52-57, 1995.

126.

Molloy MP, Herbert BR, Slade MB, Rabilloud T, Nouwens AS, Williams KL., Gooley AA.
Proteomic analysis of the Escherichia coli outer membrane Eur J Biochem 267: 8712881,2001.

127.

Moriya S, Kazlauskas A, Akimoto K, Hirai S, Mizuno K, Takenawa T, Fukui Y, Watanabe
Y, Ozaki S, Ohno S. Platelet-derived growth factor activates protein kinase C epsilon
through redundant and independent signaling pathways involving phospholipase C
gamma or phosphatidylinositoI3-kinase. Proc. Natl. Acad. Sci. USA 93:151-155,1999.

110

128.

Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell
injury in ischemic myocardium. Circulation, 74:1124-1136,1986.

129.

Newton AC. Regulation of the ABC kinases by phosphorylation: protein kinase C as a
paradigm. Biochem. J. 370:361-371,2003.

130.

O'Rourke B. Myocardial KATP channels in preconditioning. Circ Res. 87:845-855, 2000.

131.

Oh H, Fujio Y, Kunisada K, Hirota H, Matsui H, Kishimoto T, Yamauchi-Takihara K.
Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein
kinase Band p70 S6 kinase phosphorylation in cardiac myocytes. J BioI Chern 273:97039710,1998.

132.

Ohi MD, Link AJ, Ren L, Jenning JL., McDonald WH., Gould KL. Proteomics analysis
reveals stable multiprotein complexes in both fission and budding yeasts containing Mybrelated Cdc5p/Cef1 p, novel pre-mRNA splicing factors, and snRNAs. Mol Cell BioI.
22:2011-2024, 2002.

133.

Palzkill T. Proteomics. Kluwer Academic Publishers. P1-4. 2001.

134.

Pandey A, Mann M. Proteomic to study genes and genomes. Nature 405:837-846,2000.

135.

Pass JM, Zhang J, Vondriska TM, Ping P. Functional proteomic analysis of the protein
kinase C signaling system. Methods Mol BioI. 233:369-385, 2003.

136.

Pass JM, Zheng Y, Wead WB, Zhang J, Li RC, Bolli R Ping P. PKCepsilon activation
induces dichotomous cardiac phenotypes and modulates PKCepsilon-RACK interactions
and RACK expression. Am J Physiol. 88:H946-955, 2001.

137.

Passier R, Richardson JA, Olson EN. Oracle, a novel PDZ-LlM domain protein expressed
in heart and skeletal muscle Mech Dev. 92:277-284, 2000.

138.

Persad S, Attwell S, Gray V, Mawji N, Deng JT, Leung D, Yan J, Sanghera J, Walsh MP,
Dedhar S. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrinlinked kinase: critical roles for kinase activity and amino acids arginine 211 and serine
343. J BioI Chern. 276:27462-27469, 2001.

139.

Phadke ND, Molloy MP, Steinhoff SA, Ulintz PJ, Andrews PC, Maddock JR. Analysis of
the outer membrane proteome of Caulobacter crescentus by two-dimensional
electrophoresis and mass spectrometry. Proteomics 1:705-720,2001.

140.

Ping P, Takano H, Zhang J, Tang XL, Qiu Y, Li RC-X, Banerjee S, Dawn B, Balafanova
Z, Bolli R. Isoform-selective activation of protein kinase C by nitric oxide in the heart of
conscious rabbits: a signaling mechanism for both nitric oxide-induced and ischemiainduced preconditioning. Circ Res. 84:587-604, 1999.

141.

Ping P, Zhang J, Huang S, Cao X, Tang XL, Li RCX, Zheng YT, Qiu Y, Clerk A, Sugden
PH, and Bolli R. PKC-dependent activation of p46/p54 JNKs during ischemic
preconditioning in conscious rabbits. Am J Physio/277:H1771-1785, 1999.

142.

Ping P, Zhang J, Pierce WM Jr, Bolli R. Functional proteomic analysis of PKCf:: signaling
complexes in the normal heart and during cardioprotection. Cire Res 88:59-62, 2001.

111

143.

Ping P, Zhang J, Qiu Y, Tang Xl, Manchikalapudi S, Cao X, Bolli R. Ischemic
preconditioning induces selective translocation of PKC isoforms c and 11 in the heart of
conscious rabbits without subcellular redistribution of total PKC activity. Cire Res 81 :404414,1997.

144.

Ping P, Zhang J, Zheng Y, Li RCX, Dawn B, Tang Xl, Takano H, Balafanova Z, Bolli R.
Demonstration of selective protein kinase C-dependent activation of Src and lck tyrosine
kinases during ischemic preconditioning in conscious rabbits. Circ Res 85: 542-550,
1999.

145.

Ping P, Song C, Zhang J, Guo Y, Cao X, Li RC, Wu W, Vondriska TM, Pass JM, Tang
Xl, Pierce WM, Bolli R. Formation of protein kinase C(epsilon)-lck signaling modules
confers cardioprotection. J. Clin. Invest. 109,499-507,2002.

146.

Qin Q, Downey JM, Cohen MV. Acetylcholine but not adenosine triggers preconditioning
through Pl3-kinase and a tyrosine kinase Am J Physiol. 284:H727-734, 2003.

147.

Qiu Y, Ping P, Tang Xl, Manchikalapudi S, Rizvi A, Zhang J, Takano H, Wu WJ,
Teschner S, Bolli R. Direct evidence that protein kinase C plays an essential role in the
development of late preconditioning against myocardial stunning in conscious rabbits and
that c is the isoform involved. J Clin Invest 101 :2182-2198, 1999.

148.

Radomski MW, Palmer RM, Moncada S. An l-arginine/nitric oxide pathway present in
human platelets regulates aggregation. Proc Natl Acad Sci U. S. A. 57: 5193-6197,1990.

149.

Ragolia l, Palaia T, Paric E, Maesaka JK. Elevated l-PGDS activity contributes to PMAinduced apoptosis concomitant with downregulation of PI3-K. Am J Physio/284:C119-26,
2003.

150.

Raman CS, Li H, Martasek P, Kral V, Masters BS, Poulos TL. Crystal structure of
constitutive endothelial nitric oxide synthase: a paradigm for proteinn function involving a
novel metal center. Cell 95: 939-950, 1998.

151.

Reiner M, Bloch W, Addicks K. Functional interaction of caveolin-1 and eNOS in
myocardial capillary endothelium revealed by immunoelectron microscopy. J Histoehem.
49:1605-1610, 2001.

152.

Sakoda T, Hirata K, Kuroda R, Miki N, Suematsu M, Kawashima S, and Yokoyama M.
Myristoylation of endothelial cell nitric oxide synthase is important for extracellular release
of nitric oxide. Mol Cell Biochem 152: 143-148, 1995.

153.

Schagger H, Cramer WA, Jagow G. Analysis of molecular masses and oligomeric states
of protein complexes by blue native electrophoresis and isolation of membrane protein
complexes by two-dimensional native electrophoresis. Analytical biochemistry. 217: 220230,1994.

154.

Schagger H. Quantification of oxidative phosphorylation enzymes after blue native
electrophoresis and two-dimensional resolution: normal complex I protein amounts in
Parkinson's disease conflict with reduced catalytic activities. Electrophoresis. 16:763-770,
1995.

155.

Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103:211-225, 2000.

156.

Scott-Burden T, Engler DA, Tock Cl, Schwarz JJ, Casscells SW. Liposomal induction of
NO synthase expression in cultured vascular smooth muscle cells. Biochem Biophys Res
Commun. 231 :780-783, 1997.

112

157.

Sessa WC, Barber CM, and Lynch KR. Mutation of N-myristoylation site converts
endothelial cell nitric oxide synthase from a membrane to a cytosolic protein. Circ Res 72:
921-924, 1993.

158.

Shinmura K, Tang XL., Wang Y, Xuan YT, Liu SQ, Takano H, Bhatnagar A, Bolli R.
Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic
preconditioning in conscious rabbits. Proc Nat! Acad Sci USA. 97:10197-10202,2000.

159.

Smart EJ, Ying YS, Mineo C, Anderson RG. A detergent-free method for purifying
caveolae membrane from tissue culture cells. Proc Nat! Acad Sci USA. 92:1010410108, 1995.

160.

Song C, Vondriska TM, Wang G, Klein JB, Cao X, Zhang J, Kang YJ, D'Souza S, Ping P.
Molecular conformation dictates signaling module formation: example of PKCe- and Src
tyrosine kinase. Arn J Physiol. 282:H1166-1171, 2002.

161.

Sonnenburg ED, Gao T, Newton AC. The phosphoinositide dependent kinase, PDK-1,
phosphorylates conventional protein kinase C isozymes by a mechanism that is
independent of phosphoinositide-3-kinase. J. Bioi. Chern., 276:45289-45297, 2001.

162.

Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB,
Gaffney PR, Reese CB, McCormick F, Tempst P, Coadwell J, Hawkins PT. Protein
kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent
activation of protein kinase B. Science 279:710-714, 1998.

163.

Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter GF, Holmes AB,
McCormick F, Hawkins PT. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the
activation of protein kinase B. Science 277:567-570,1997.

164.

Takahashi M, Mukai H, Oishi K, Isagawa T, Ono Y. Association of immature
hypophosphorylated protein kinase c epsilon with an anchoring protein CG-NAP. J. Bioi.
Chern. 275:34592-34596, 2000.

165.

Toker A, Newton AC. AktJprotein kinase B is regulated by autophosphorylation at the
hypothetical PDK-2 site. J Bioi Chern 275:8271-8274,2000.

166.

Tong H, Chen W, Steenbergen C, Murphy E. Ischemic preconditioning activates
phosphatidylinositol-3-ki-nase upstream of protein kinase C. Circ. Res. 87:309-315,
2000.

167.

Uemura K, Aki T, Yamaguchi K, Yoshida K. Protein kinase C-epsilon protects PC12 cells
against methamphetamine-induced death: possible involvement of suppression of
glutamate receptor. Life Sci. 21;72:1595-1607, 2003.

168.

Van Eyk, J.E. Proteomics: unraveling the complexity of heart disease and striving to
change cardiology.Curr Opin Mol Ther. 3: 546-553, 2001.

169.

Venema RC, Ju H, Zou R, Ryan JW, Venema VJ. Subunit interactions of endothelial
nitric-oxide synthase. Comparisons to the neuronal and inducible nitric-oxide synthase
isoforms. J Bioi Chern 272: 1276-1282, 1997.

170.

Vondriska TM, Ping P. Functional proteomics to study protection of the ischaemic
myocardium. Experl Opin Ther Targets. 6:563-570, 2002.

113

171.

Vondriska TM, Zhang J, Ping P. Proteomic characterization of protein kinase C signaling
tasks in the heart. Proteomic and genomic analysis of cardiovascular disease. Edited by
Van Eyk JE, Dunn MJ.wiley-VCH, p293-306, 2002.

172.

Vondriska TM, Zhang J, Song C, Tang XL, Cao X, Baines CP, Pass JM, Wang S, Bolli R,
Ping P. PKCe-Src modules directs signal transduction in nitric oxide-induced
cardioprotection: complex formation as a means for cardioprotective signaling. Circ Res
88:1306-1313, 2001.

173.

Vondriska TM, Klein JB., Ping P. Use of functional proteomics to investigate PKC
epsilon-mediated cardioprotection: the signaling module hypothesis. Am J Physiol.
280:H1434-1441, 2001.

174.

Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods used in circulation
research. Circ Res. 47:1-9,1980.

175.

Wasinger VC, Cardwell SJ, Cerpa-Poljak A, Yan JX, Gooley AA, Wilkins MR, Duncan
MW, Harris R, Williams KL, Humphery-Smith IProgress with gene-product mapping of the
Mollicutes: Mycoplasma genitalium. Electrophoresis. 16:1090-1094, 1995.

176.

Wen HC, Huang WC, Ali A, Woodgett JR, Lin WW. Negative regulation of
phosphatidylinositol 3-kinase and Akt signaling pathway by PKC. Cell Signal. 15:37-45,
2003.

177.

Williams MR, Arthur JS, Balendran A, van der Kaay J, Poli V, Cohen P, Alessi DR. The
role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined
in embryonic stem cells. Curr BioI 10:439-448, 2002.

178.

Wu CC, Taylor RS, Lane DR, Ladinsky MS, Weisz JA, Howell KE. GMx33: a novel family
of trans-Golgi proteins identified by proteomics. Traffic, 1: 963-75, 2000.

179.

Xi L, Kukreja RC. Pivotal role of nitric oxide in delayed pharmacological preconditioning
against myocardial infarction. Toxicology 155:37-44, 2000.

180.

Xu KY, Huso DL, Dawson TM, Bredt OS, Becker LC. Nitric oxide synthase in cardiac
sarcoplasmic reticulum. Proc Nat! Acad Sci. 96:657-662,1999.

181.

Xuan YT, Tang XL, Qiu Y, Banerjee S, Takano H, Han H, Bolli R. Biphasic response of
cardiac NO synthase isoforms to ischemic preconditioning in conscious rabbits. Am J
Physiol. 279:H2360-2371" 2000.

182.

Yamashita K, Kajstura J, Discher OJ, Wasserlauf BJ, Bishopric NH, Anversa P, Webster
KA. Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts
overexpressing insulin-like growth factor-1. Circ Res. 88:609-614, 2001.

183.

Yang J, Corn P, Thompson V, Good VM, Hess 0, Hemmings BA, Barford D. Molecular
mechanism for the regulation of protein kinase B/Akt by hydrophobic motif
phosphorylation. Mol Cell 9: 1227-40, 2002.

184.

Yet SF, Tian R, Layne MD, Wang ZY, Maemura K, Solovyeva M, Ith B, Melo LG, Zhang
L, Ingwall JS, Dzau VJ, Lee ME, Perrella MA. Cardiac-specific expression of heme
oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ
Res. 89:168-173, 2001.

114

185.

Yoshizumi M, Perrella MA, Burnett JC Jr, and Lee ME. Tumor necrosis factor
downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Cire
Res 73: 205-209, 1993.

186.

Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein
kinase C activation. Am J Physiol 266: H1145-1152, 1994.

187.

Zhang J, Patel JM, Li YO, and Block ER. Proinflammatory cytokines downregulate gene
expression and activity of constitutive nitric oxide synthase in porcine pulmonary artery
endothelial cells. Res Commun Mol Pathol Pharmaeo/96: 71-87, 1997.

188.

Zhou HZ, Karliner JS, Gray MO. Moderate alcohol consumption induces sustained
cardiac protection by activating PKC-epsilon and Akt. Am J Physiol. 283:H165-174, 2002.

189.

Zhou 0, Chu PH, Huang C, Cheng CF, Martone ME, Knoll G, Shelton GO, Evans S,
Chen J. Ablation of Cypher, a PDZ-LlM domain Z-line protein, causes a severe form of
congenital myopathy. J Cell 8iol. 155:605-612, 2001.

190.

Ziegler WH, Parekh DB, Le Good JA, Whelan RD, Kelly JJ, Frech M, Hemmings BA,
Parker PJ. Rapamycin-sensitive phosphorylation of PKC on a carboxy-terminal site by an
atypical PKC complex. Curr 8io/9:522-529, 1999.

115

CURRICULUM VITAE

Name:

Jun Zhang

Present Address:

Department of Physiology & Biophysics,
Health science center, A Bldg., RM 1105
University of Louisville, KY, 40202

Phone:

(502) 339-9232 (Home)
(502) 852-5379 (Office)

Fax:
Email:

(502) 852-6239
Julyjun@yahoo.com

EDUCATION

08/2001-Present:

Doctoral student, Department of Physiology/Biophysics,
University of Louisville. U.S.A. Major: Physiology

08/1991-07/1994:

Master of Science, Institute of Microbiology,
Chinese Academy of Sciences. P.R.China. Major: Biochemistry.

09/1987 - 07/1991:

Bachelor of Science, Dept. of Microbiology,
Shandong University, P.R.China. Major: Microbiology.

EMPLOYMENT AND WORKING EXPERIENCE

01/1996 -12/2002:

Senior Research Associate
Dept. of Physiology and Biophysics / Division of Cardiology,
SctlOol of Medicine, University of Louisville. U.S.A.

08/1994 - 12/1995:

Research Associate
Dept. of Molecular Biology, Institute of Microbiology,
Chinese Academy of Sciences. P.R.China.

HONORS AND AWARDS

1.

2001: Trainee Abstract Award: American Heart Association, Scientific Sessions, Anaheim,
CA.

116

2.

1993: Third Prize in Young Scientific Research Presentation of Chinese Academy of
Sciences, P.R.China.

SOCIETY MEMBERSHIP
Member, International Society for Heart Research.
Fellow, American Heart Association, Basic Sciences Council

PUBLICATIONS
1.

Zhang J, Baines CP, Vondriska TM, Cardwell EM, Zong C, Wang GW, Ping P.
Characterization of myocardial PKCE-Akt-eNOS signaling modules via functional proteomic
analysis. (in preparation)

2.

Zhang J, Baines CP, Vondriska TM, Zong C, Cardwell EM, Wang GW, loo R, Ping P.
Functional proteomic mapping of the myocardial PKCE signaling subproteome in the mouse
heart: a subcellular compartment study. (Submitted to Proteomics)

3.

Zhang J, Ping P, Vondriska TM, Tang Xl, Wang GW, Cardwell EM, Bolli R. Cardioprotection
involves activation of NF-KB via PKC-dependent tyrosine and serine phosphorylation of IKBu. Am J Physiol. 200:-1; 285:H1753-1758.

4.

Baines CPo Song CX, Zheng YT, Wang GW, Zhang J, Wang Ol, Guo Y, Bolli R, Cardwell
EM, Ping P. Protein kinase C epsilon interacts with and inhibits the permeability transition
pore in cardiac mitochondria. Cire Res. 2003; 92(8):873-880.

5.

Edmondson RD, Vondrika TM, Biedermant KJ, Zhang J, Jones RC, Zheng YT, Allen Dl, Xiu
JX, Cardwell EM, Pisano MR, Ping P. Protein kinase C E signaling complexes include
metabolism-and transcription/translation-related proteins. Mol Cell Proteomies. 2002; 1:421433.

6.

Baines CP, Zhang J, Wang GW, Zheng YT, Xiu JX, Cardwell EM, Bolli R, Ping P.
Mitochondrial PKC epsilon and MAPK form signaling modules in the murine heart: enhanced
mitochondrial PKC epsilon-MAPK interactions and differential MAPK activation in PKC
epsilon-induced cardioprotection. Cire Res. 2002; 90:390-397.

7.

Ping P, Song C, Zhang J, Guo Y, Cao X, Li RC, Wu W, Vondriska TM, Pass JM, Tang Xl,
Pierce WM, Bolli R. Formation of protein kinase C(epsilon)-lck signaling modules confers
cardioprotection. J Clin Invest. 2002; 109:499-507.

8.

Balafanova Z, Bolli R, Zhang J, Zheng Y, Pass JM, Bhatnagar A, Tang Xl, Wang 0,
Cardwell E, Ping P. Nitric oxide induces nitration of PKC epsilon, facilitating PKC epsilon
translocation via enhanced PKC epsilon-RACK2 interactions: A novel mechanism of NOtriggered activation of PKC epsilon. J Bioi Chem. 2002; 277:15021-15027.

9.

Song C, Vondriska TM, Wang GW, Klein JB, Cao X, Zhang J, Kang YJ, D'Souza S, Ping P.
Molecular conformation dictates signaling module formation: example of PKC epsilon and Src
tyrosine kinase. Am J Physiol. 2002; 282:H1166-1171.

117

10. Pass JM, Gao J, Jones WK, Wead WB, Wu X, Zhang J, Baines CP, Bolli R, Zheng YT,
Joshua IG, Ping P. Enhanced PKC beta II translocation and PKC beta II-RACK1 interactions
in PKC epsilon-induced heart failure: a role for RACK1 Am J Physiol. 2001; 281 :H25002510.
11. Zhang J, Vondriska TM, Song C, Tang XL, Cao X, Baines CP, Pass JM, Wang S, Bolli R,
Ping P. Protein kinase C epsilon-Src modules direct signal transduction in nitric oxideinduced cardioprotection: complex formation as a means for cardioprotective signaling. Circ
Res. 2001; 88: 1306-1313.
12. Pass JM, Zheng Y, Wead WB, Zhang J, Li RC, Bolli R, Ping P. PKC epsilon activation
induces dichotomous cardiac phenotypes and modulates PKC epsilon-RACK interactions
and RACK expression. Am J Physiol. 2001; 280:H946-955.
13. Ping P, Zhang J, Pierce WM Jr, Bolli R. Functional proteomic analysis of protein kinase C
epsilon signaling complexes in the normal heart and during cardioprotection. Circ Res. 2001;
88:59-62.
14. Li RCX, Ping P, Zhang J, Wead WB, Cao X, Gao J, Zheng Y, Huang S, Han J, Bolli R. PKC
epsilon modulates NF-kappa Band AP-1 via mitogen-activated protein kinases in adult rabbit
cardiomyocytes. Am J Physiol. 2000; 279:H1679-1689.
15. Ping P, Zhang J, Huang S, Cao X, Tang XL, Li RC, Zheng YT, Qiu Y, Clerk A, Sugden P,
Han J, Bolli R. PKC-dependent activation of p46/p54 JNKs during ischemic preconditioning in
conscious rabbits. Am J Physiol. 1999; 277:H1771-1785.
16. Ping P, Zhang J, Zheng YT, Li RCX, Dawn B, Tang XL, Takano H, Balafanova Z, Bolli R.
Demonstration of selective protein kinase C-dependent activation of Src and Lck tyrosine
kinases during ischemic preconditioning in conscious rabbits. Circ Res. 1999; 85:542-550.
17. Ping P, Zhang J, Cao X, Li RCX, Kong D, Tang XL, Qiu Y, Manchikalapudi S, Auchampach
JA, Black RG, Bolli R. PKC-dependent activation of p44/p42 MAPKs during myocardial
ischemia-reperfusion in conscious rabbits. Am J Physiol. 1999; 276:H1468-1481.
18. Ping P, Takano H, Zhang J, Tang XL, Qiu Y, Li RCX, Banerjee S, Dawn B, Balafonova Z,
Bolli R. Isoform-selective activation of protein kinase C by nitric oxide in the heart of
conscious rabbits: a signaling mechanism for both nitric oxide-induced and ischemia-induced
preconditioning. Circ Res. 1999; 84:587-604.
19. Bolli R, Dawn B, Tang XL, Qiu Y, Ping P, Xuan YT, Jones WK, Takano H, Guo Y, Zhang J.
The nitric oxide hypothesis of late preconditioning. Basic Res Cardio/. 1998; 93:325-338.
20. Qiu Y, Ping P, Tang XL, Manchikalapudi S, Rizvi A, Zhang J, Takano H, Wu WJ, Teschner
S, Bolli R. Direct evidence that protein kinase C plays an essential role in the development of
late preconditioning against myocardial stunning in conscious rabbits and that epsilon is the
isoform involved. J Clin Invest. 1998; 101 :2182-2198.
21. Ping P, Zhang J, Qiu Y, Tang XL, Manchikalapudi S, Cao X, Bolli R. Ischemic
preconditioning induces selective translocation of protein kinase C isoforms epsilon and eta
in the heart of conscious rabbits without subcellular redistribution of total protein kinase C
activity. Circ Res. 1997; 81 :404-414.
22. Zhang J, Xu JL. Oleyl oleate synthesis by immobilized lipase from Candida sp.-1619.
Chinese J of Biotechnology.1995; 11 :243-252.

118

23. Xu JL, Zhang J. Studies on the lipase from Penicillium Camemberlii-PG3. Acta Mvcologica
Sinica. 1995; 14:136-142.
24. Zhang J, Xu JL. Oleyl oleate synthesis by immobilized lipase from Candida sp.-1619.
Chinese Journal of Biotechnology. 1995; 11 :325-331.

SELECTED ABSTRACTS
1.

Zhang J, Zong C, Vondriska TM, Qiao X, Cardwell EM, Ping P. Proteomic mapping of
cardiac protective signaling complexes using blue native electrophoresis and bioinformatic
modeling. FASEB J. 2003; 17:A76.

2.

Vondriska TM, Zhang S, Zhang J, Qiao X, Zheng YT, Cardwell EM, Ping P. Oracle regulates
cardiac PKCe signaling complexes in preconditioning. FASEB J. 2003; 17:A106.

3.

Zhang S, Baines CP, Zhang J, Vondriska TM, Qiao X, Guo Y, Bhatnagar A, Bolli R, Ping P,
Wang GW. Acrolein exacerbates ischemic injury in the heart and disrupts PKCe protective
signal transduction. FASEB J.. 2003; 17:A880.

4.

Zhang J, Vondriska TM, Wang GW, Baines CP, Stidam JM, Cardwell EM, Ping P.
Characterization of a signaling complex by its protein composition, molecular architecture,
and spatial distribution: defining the role of PKCe-Akt-eNOS modules in cardioprotection via
functional proteomics. Circulation. 2002; 106:11-6.

5.

Ping P, Zhang J, Vondriska TM, Guo Y, Stidam JM, Cardwell EM, Wang GW, Bolli R.
Cardiac-specific transgenesis of iNOS confers an infarct-sparing effect: signaling
mechanisms involve site-specific iNOS tyrosine phosphorylation by Src tyrosine kinase.
Circulation. 2002; 106: II-56.

6.

Zheng YT, Vondriska TM, Zhang J, Edmondson RD, Ping P. Oracle, a PDZ and LIM domaincontaining protein, particulate in PKCe protective signaling complexes at distinct subcellular
locations in the heart. Circulation. 2002; 11-312.

7.

Baines CP, Song C-X, Edmondson RD, Beiderman KJ, Jones RC, Zhang J, Cao X, Ping P.
Functional proteomic analysis reveals an interaction between protein kinase Ce and the
voltage-dependent anion channel in cardiac mitochondria. FASEB J. 2002; 16:A883.

8.

Zhang J, Wang G-W, Baines CP, Zheng YT, Ping P. Protein kinase Ce forms a signaling
module with Akt and eNOS: differential modulation by myocardial protection and myocardial
toxicity. FASEB J. 2002; 16:A177.

9.

Zhang J, Bolli R, Zheng YT, Xiu J, Wang GW, Pierce WM, Ping P. Subcellular location is a
major determinant of PKCe complex assembly: a view gained via functional proteomic
analyses in cardioprotection. Circulation. 2001, 104: 11-209.

10. Vondriska TM, Tang XL, Zhang J, Bolli R, Ping P. Bmx, a member of the Tec family of nonreceptor tyrosine kinases, is a novel participant in the signaling system of NO-induced
cardioprotection. Circulation. 2001, 104: 11-61.
11. Baines CP, Wang GW, Zhang J, Zheng YT, Klein JB, Kang YJ, Bolli R, Ping P. Mitochondrial
co-localization of MAPK with PKCe in the murine heart: increased mitochondrial PKCe-MAPK
signaling module formation in PKCe transgenic mice. Circulation. 2001, 104: 11-102.

119

12. Vondriska TM, Ping P, Zhang J, Tang XL, Bolli R. PKCe-dependent upregulation of PKCe
activity during nitric oxide-induced cardioprotection. Circulation. 2001, 104: 11-208.
13. Song C, Zhang J, Cao X, Vondriska TM, Bolli R, Ping P. Conformation of molecules dictates
signaling module formation: example of PKCe and Src tyrosine kinase. Circulation. 2001,
104: 11-210.
14. Baines CP, Zhang J, Zheng YT, Xiu JX, Bolli R, Ping P. Transgenic activation of PKCe
preferentially increases mitochondrial PKCe expression and enhances formation of a
mitochondrial PKCe-JNK signaling complex in the mouse heart. FASEB J. 2001; 15:A 103.
15. Vondriska TM, Zhang J, Tang XL, Bolli R, Ping P. Src tyrosine kinase forms a signaling
complex with PKCe during NO-induced preconditioning that is subcellular compartmentspecific and PKCe activation-dependent. FASEB J. 2001; 15:A 119.
16. Vondriska TM, Edmondson R, Zhang J, Biederman K, Zheng Y, Jones R, and Ping P.
Functional proteomics: PKCe··mediated cardioprotective signaling involves metabolism- and
transcription/translation-related proteins. AHA Myocardial Ischemia Meeting. 2001.
17. Vondriska TM, Song C, Wang G, Cao X, Zhang J, D'Souza S, Bolli R, and Ping P. Molecular
conformation determines protein-protein interactions between PKCe and Src tyrosine kinase.
2001. AHA Myocardial Ischemia Meeting. 2001.
18. Wang GW, Zhang J, Baines CP, Song CX, Zheng YT, Klein JB, Kang YJ, Bolli R, Ping P.
Cardioprotection involves subcellular compartment-dependent localization of PKCe-Src and
PKCe-Lck signaling modules. J Mol Cell Cardiol. 2001.
19. Vondriska TM, Zhang J, Song C, Tang XL, Bolli R, Ping P., PKCe-Src modules direct signal
transduction in NO-induced cardioprotection: Complex formation as a means for
cardioprotection. J Mol Cell Cardiol (suppl.), 2001
20. Song CX, Cao X, Zhang J, Vondriska TM, Bolli R, Ping P. PKCe binds to and activated Src
tyrosine kinase in vitro: Characterizing a cardiac PKCe-Src module. J Mol Cell Cardiol
(suppl.), 2001.
21. Balafanova Z, Gao JM, Zhang J, Bolli R, Ping P. Nitric oxide induces activation of PKCe via a
cGMP-dependent mechanism in adult rabbit cardiac myocytes. J Mol Cell Cardiol. 2001;
33:A7.
22. Pass J, Zhang J, Zheng YT, Bolli R, Ping P. Enhanced PKC~II translocation and PKC~II
RACK1 interactions in PKCe-induced cardiac hypertrophy and failure: a role for RACK1. d.
Mol Cell Cardiol. 2001; 33:A90.
23. Ping P, Zhang J, Zheng YT, 'Li CX, Guo YR, Bao WK, Bolli R. Cardiac targeted transgenesis
of active PKC epsilon renders the heart resistant to infarction. Circulation 2000, 102: 11-24.
24. Ping P, Guo YR, Zhang J, 'Li CX, Bao WK, Wu WJ, Bolli R. Targeted deletion of Lck
tyrosine kinase abrogates the NF-kappa B activation and the infarct-sparing effect induced by
late preconditioning. Circulation 2000, 102: 11-211.
25. Song C, Zhang J, Gao JM, Zheng YT, Cao X, Wead WB, Bolli R, Ping P. Lck tyrosine kinase
is a direct substrate of PKC epsilon in cardiac myocytes. Circulation 2000, 102: 11-211.

120

26. Pass JM, Zheng YT, Zhang J, Li CX, Bolli R, Ping P. Dichotomous cardiac phenotypes are
congruous with differential interactions between protein kinase C epsilon and its receptor
proteins. Circulation 2000, 102: 11-160.
27. Li CX, Zhang J, Zheng YT, Wead WB, Gao JM, Cao X, Bolli R, Ping P. PKC epsilon
enhances NF-kappa B activation via modulation of IKK complex in cardiac myocytes.
Circulation 2000, 102: 11-120.
28. Ping P, Zhang J, Bolli R. Functional proteomic analysis of protein kinase C E signaling
complexes in preconditioning. Circulation 2000, 102: 11-221.
29. Pass JM, Zhang J, Li CX, Zheng YT, Bolli R, Ping P. Stochiometric analyses of PKC and
RACK expression in the FVBN mouse heart. J Mol Cell Cardiol. 2000, 32: A25.
30. Gao JM, Zheng YT, Zhang J" Bolli R, Li CX, Wead WB, Ping P. Transgenic overexpression
of the T] isoform of PKC does not trigger cardiac hypertrophy. J Mol Cell Cardiol. 2000; 32:
A58.
31. Zhang J, Bolli R, Tang XL, Jones WK, Ping P. Direct demonstration of both tyrosine and
serine phosphorylation of IKB during ischemic preconditioning in conscious rabbits.
Circulation 1999, 100: I-56.
32. Zhang J, Bolli R, Lalli J, Tang XL, Li CX, Zheng YT, Pass JM, Ping P. Ischemic
preconditioning and phorbol ester redistribute protein kinase C E to the nucleus, sarcolemmal
membranes, and mitochondria in rabbit myocardium. Circulation 1999,100: 1-325.
33. Li CX, Ping P, Zhang J, Joshua IG, Zheng YT, Gao JM, Bolli R. Protein kinase C epsilon
activates nuclear factor-KappaB through a Src-Dependent signaling pathway in adult rabbit
cardiac myocytes. Circulation 1999, 100: 1-325.
34. Li CX, Ping P, Zhang J, Cao X, Zheng YT, Gao JM, Xuan YT, Wead WB, Joshua IG, Bolli
R. PKCE activates NFKB and AP-1 via a ERK-dependent signaling pathway in the adult rabbit
cardiac myocytes. J Mol Cell Cardiol. 1999, 31: A 18.
35. Zhang J, Wead WB, Jones WK, Wu X, Gao JM, Kong DY, Li CX, Zheng YT, Ping P.
Activation of PKCE. induces hypertrophy and heart failure in a dose-dependent fashion in
mice. J Mol Cell Cardia I. 1999,31: A18.
36. Pass JM, Zhang J, Zheng YT, Li CX, Ping P. RACK expression is coordinated with PKCE
. expression in the mouse heart. J Mol Cell Cardiol. 1999, 31: A 19.
37. Ping P, Li RCX, Zhang J, Kong D, Jones WK, Zheng YT, Cao X, Bolli R. Identification of two
distinct mechanisms for the activation of p44/p42 MAPKs in vivo by a PKC epsilon dependent
signaling pathway in transgenic mice. Circulation 1998, 98:1-416.
38. Ping P, Zhang J, Li CX, Tang XL, Qiu Y, Banerjee S, Zheng YT, Bolli R. Ischemic
preconditioning (PC) induces selective activation of Src and Lck tyrosine kinases in
conscious rabbits via a PKC-dependent pathway. Circulation 1998,98:1-71.
39. Ping P, Zhang J, Cao X, Kong D, Tang XL, Qiu Y, Manchikalapudi S, Li CX, Bolli R. Brief
episodes of ischemia induce activation of the MEK1/2-p44/p42 MAPK signaling cascade in
the cytosolic fraction and subsequent nuclear translocation of p44/p42 MAPKs via a PKCdependent pathway in conscious rabbits. Circulation 1998; 98:1-586.

121

40. Ping P, Kong D, Jones WK, Li CX, Zhang J, Cao X, Wu X, Wead WB, Harris PD, Joshua IG,
Bolli R. Cardiac targeted expression of PKC epsilon isoform selectively alters PKC activity in
the mouse heart. FASEB J. 1998, 12:A-75.
41. Ping P, Zhang J, Cao X, Qiu V, Tang XL, Clerk A, Sugden P, Bolli R. Activation of the
P38MAPK and the p46/p54 JNKs after brief episodes of ischemia/reperfusion in the heart of
conscious rabbits. J Mol Cell Cardiol. 1998, 30: A-263.
42. Ping P, Cao X, Kong D, Zhang J, Li CX, Vang V, Bolli R. PKC epsilon isoform induces
activation of the p42/p44 MAPKs and the p46/p54 JNKs in adult rabbit cardiac myocytes. J.
Mol Cell Cardiol. 1998; 30:A-263.
43. Ping P, Zhang J, Qiu V, Tang XL, Manchikalapudi S, Bolli R. Repetitive episodes of
myocardial ischemia and reperfusion induce translocation of protein kinase C epsilon isoform
in conscious rabbits, which is associated with late preconditioning against myocardial
stunning. Circulation 1996; 94:1-660.
44. Xu JL, Zhang J. Lipase catalyzed synthesis of 2-ethyl hexanol fatty acid esters. Oral
presentation, the fourth China-Japan Joint symposium on Enzyme Engineering, Oct., 1996.
45. Zhang J, Jia-Li Xu. Hydrolysis and Synthesis of Oleyl Oleate Catalyzed by Lipases. Poster
presentation, the Second National Conference on Enzyme Engineering, Acta Scientiarum
Naturalium Universitatis Jilinensis 1993, P4-6.
46. DD Gu, J.I. Xu, Zhang J. Immobilization of Candida sp.-1619 Lipase for Synthesis waxesters. Poster presentation, the Second National Conference on Enzyme Engineering, Acta
Scientiarum Naturalium Universitatis Jilinensis 1993, P4-7.

BOOK CHAPTERS:
1.

Pass PM, Zhang J, Vondriska TM, Ping P. (Newton AC eds.) Functional proteomic analysis
of the protein kinase C signaling system. Protein kinase C protocols, Methods in molecular
biology, 233: 369-385, Humana Press, 2003.

2.

Vondriska TM, Zhang J, Ping P. (Van Eyk JE and Dunn MJ, eds.) Proteomic characterization
of protein kinase C signaling tasks in the hearts. Proteomic and genomic analysis of
cardiovascular disease. Wiley-VCH, 2003.

3.

Baines CP, Zhang J, Ping P. Characterization of mitochondrial signaling complexes. Ping P,
Hanash S, eds. Functional proteomics: principles and practical applications. The Humana
Press Inc. (in press).

4.

Rokosh G and Zhang J Co-editors. Cardiac genes expression and regulation. Methods in
molecular biology, Humana Press. (in preparation)

NATIONAL MEETING ORAL PRESENTATION
th

Oral presentation: American Heart Association 75 Scientific Sessions, Chicago, IL. Title:
Characterization of a signaling complex by its protein composition, molecular architecture, and
spatial distribution: defining the role of PKCE-Akt-eNOS modules in cardioprotection via functional
proteomics. November 11,2002.

122

